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Abstract
Models of the homodimer of HNF4a (Hepatocyte Nuclear Factor 4 a) were built, based on the 
crystal structures of two domains, the DNA binding domain (DBD) and ligand binding domain 
(LBD) that form a significant portion of the complete structure (amino acids 49-369 of 455). 
Molecular dynamics simulations of the resultant models have revealed some interesting insights 
into a more complete structure than the separate crystal structures indicate. These are a novel area 
of dimerization between two monomers of a homodimer, novel interactions between monomers 
in previously investigated regions; that have the potential to be areas in which mutations may 
cause a disruption to the structure and/ or function of the homodimer. A potential explanation as 
to the repressive function of the repressor region found at the C-terminus of the sequence is also 
postulated.
X-ray crystal structures of the antibiotic oligomycin (forms A, B and C) published by Palmer and 
Potter, 2008, were investigated to examine their binding to ATP Synthase. The x-ray crystal 
structure of the A form showed some anomalous features which were investigated with the aid of 
ab initio molecular orbital calculations. A model of the ATP Synthase Fo domain was modified 
by the addition of a missing segment of the stationary subunit a. The new model was used in a 
series of protein-ligand docking studies of the x-ray crystal structures of the antibiotic 
oligomycin, which were used as starting conformations for the docking studies. It was shown that 
oligomycin binds to the proton translocating residues of the ATP Synthase Fo domain, preventing 
both the passage of protons across the membrane and the rotation of the c-ring that results in the 
catalysis of ATP synthesis. It was shown that the forms of oligomycin that were the most 
effective inhibitors were the B and C forms, despite the natural abundance of the A form. 
Calculated binding constants for the bound conformations of all three forms correlate with the 
reported experimental values for a mix of all three forms.
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Chapter 1 - Introduction
Introduction
Computational methods have become an important tool in the study of biological molecules and 
their interactions, to further understand the mechanisms of protein-protein and protein-drug 
interactions. This approach allows a researcher to view and interact directly with biological 
molecules at an atomic level. In this thesis computational methods are employed to study how 
homology modelling can provide novel information on: 1) how models provide insight into 
protein interactions with each other and mutations that may contribute to genetic conditions such 
as diabetes, 2) the study of how a recently crystallized, well known antibiotic and its different 
forms, interact as an inhibitor of energy production for E. coli', leading to its inactivation.
In the first case: a model of the nuclear receptor (NR) HNF4a (Hepatocyte Nuclear Factor 4a) 
was built and analysed in order to shed light on where mutations may occur to cause early onset 
diabetes. This is done by looking at where these interactions and mutations take place with in the 
structure. This will also provide information as to where in the structure a mutation, which has 
not been observed, may cause potential problems in the function of HNF4a.
In the second case: a recent crystallization of a well known antibiotic (oligomycin), was used to 
probe the binding site of the antibiotic showing how it inhibits the function of the E. coli ATP 
Synthase.
HNF4a
HNF4a is NR that is known to be involved in development of growth, metabolism and regulation 
of other NRs. HNF4a plays an important role in the regulation of transcription of genes required 
for good liver function. HNF4a is found throughout the body, at low levels in the pancreas and 
stomach and at higher levels in the liver, kidneys small intestine and colon. It was first found in 
rat liver nuclear extracts that bind DNA elements (7).
HNF4a and the nuclear receptor family
HNF4a is a member of the NR superfamily; this family plays roles in growth, metabolism, 
reproduction, differentiation (change of cells and or tissues toward a specialised function) and 
morphogenesis (change of tissues and cells resulting in establishing the form and structure of 
organs and parts of the body). They act as transcription factors where they bind DNA to regulate 
gene expression (2). In humans there have been 48 NR genes identified. A common feature of
- 1 -
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these is that they all consist of a series of functional modules (Figure 3) (3). HNF4a defines a 
unique class of NR; these are grouped according to how they bind to DNA and how and where 
they dimerise. HNF4a is unique as it is the only NR that binds exclusively to direct repeats as 
homodimers (4) (Figure 1).
HNF4 defines a novel subgroup of 
receptors
IGroup
Cytoplasm
III
Nucleus
Binding site 
Receptors
^ f /tr
M . . .
Steroid
hormones
-QWO I ■
f  £
m
_c*(0-5) _ >
Retinoids 
Thyroid hormone 
Vitamin D 
Ecdysone
J k
NGFI-B
SF-1
-~<1>—e-
HNF4
Figure 1: HNF4 exclusively forms homodimers only in the nucleus and binds DNA elements consisting of 
direct repeats defining a unique subfamily of NR, suggesting the mechanism of action is different from that of 
other receptors. Image from: http://www.sladeklab.ucr.edu/images/H4 subfaml.png correct as of 24/08/10 
and adapted from (4).
The HNF4a role in D iabetes mellitus
HNF4a has been widely accepted as the main gene in which mutations lead to MODY1 
(maturity-onset diabetes of the young 1) (5-S) as well as numerous other genetic conditions and 
diseases such as haemophilia (7). MODY1 is characterised by defective glucose-stimulated 
insulin secretion which is in turn caused my mutations in HNF4a (9). HNF4a is part of a 
complex transcription network that includes the regulation of H N Fla, a transcription factor 
involved in the tissue specific regulation of liver genes and insulin-secreting pancreatic p-cells (3, 
10). There are numerous mutations associated with HNF4a (Table 1), in this thesis the focus is 
on amino acid changes and not insertions or deletions.
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Chapter 1 - Introduction
HNF4a structure and function
The amino acid sequence of HNF4a identified it as a NR with a conserved DNA Binding 
Domain (DBD) and Ligand Binding Domain (LBD), and is evolutionarily close to the RXR 
(Retinoid X Receptor) family with near to 60% identity to the DBD and around 38% identity 
in the LBD between HNF4al and RXRa (Figure 2).
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Figure 2: Amino acid conservation of HNF4a genes across species and in comparison to other HNF4 
genes and the closest relative in the NR superfamily, RXR (1).
The domain organisation with in the amino acid sequence is consistent across the nuclear 
receptor family (Figure 3), with varying degrees of similarity between the domains. In 
general, the DBD (C: Figure 3) is the most conserved; and to a lesser extent, that of the LBD 
(E: Figure 3). The A/B domain (A/B: Figure 3) and F-domains (F: Figure 3) are less well 
conserved and vary in their sequence length much more across the NR family (3, 12).
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Ligand binding 
Dimerization
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i—i
AF-1 AF-2
DNA binding
Figure 3: General schematic representation of the domains and their organisation with in the sequence 
for a NR. AF-1: Activation Function 1. AF-2: Activation Function 2. (2)
HNF4a potentially has nine different isoforms (HNF4al to HNF4a9) as defined by naturally 
occurring splicing events in the HNF4a gene (Figure 4) (1).
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Figure 4: Structure of the human HNF4a gene and the isoforms generated by alternative splicing events. 
Shaded/ hatched regions denote insertions to the basic isoform (HNF4al) (1).
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A/B domain
The A/B domain (A/B: Figure 3) contains the AF-1 domain which is at least partially 
responsible for lipid metabolism, determined when a l  (without the AF-1 domain)-only mice 
presented with slight hepatic steatosis (small lipid droplets evenly distributed throughout the 
liver). It was shown that the AF-1 domain is required for the recruitment of cofactors that 
would give the isoform the capacity to regulate the expression of genes such as CAR 
(constitutive androstane receptor) (13).
Mutational analysis with in the AF-1 domain, designed to investigate its correct function, 
revealed that the aromatic residues Tyr6, Tyrl4 and Phel9 are required for activity; as are 
bulky hydrophobic residues at positions 10 and 17 and that acidic residues are preferred at 
positions 1, 4 and 9. Switching adjacent amino acids showed that the primary structure/ 
sequence order is crucial for AF-1 function (13).
It was found that there are two sub-domains (A and B) that make up the AF-1 domain. 
Module A spans from residues 1 to 12, followed by module B from 13 to 24, the two modules 
are reported to act synergistically to activate transcription. This conclusion was drawn after 
mutations that individually broke up the modules left one or the other intact. This revealed 
that the activity for a single module was less than the overall activity; showing that each 
module on its own was capable of only 10% of the total AF-1 activity. This indicates that 
both modules are necessary for full activity; however it was shown that they do not have 
equivalent functions but act in synergy with each other to activate transcription, perhaps with 
different transcription factors. The individual, separate modules were found to exhibit 
different properties in interaction assays with other proteins; module A was found to not 
interact with any of the proteins tested, whereas module B bound strongly to all the proteins 
tested. This is further evidence that there are two discrete modules with in the AF-1 and that 
they may well have distinct structural features. Interestingly even though module B bound 
more strongly than module A, it also had a lower activity; this indicates that it is forming 
non-productive complexes with the transcription targets that prevent effective signalling to 
the initiation complex. This can lead to the assumption that there is a cooperative binding of 
the two modules to either the same or different proteins through sites on the modules, with 
complementary varying affinities. Alternatively module A does have high affinity for 
cofactors and/or other general transcription factors (GTF) not tested in the study. However, if 
it is the case that there is cooperative binding and therefore a synergistic activation, the low 
affinity of module A would be key in the combinatorial use of coactivators and GTFs (14).
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DNA binding domain (DBD)
The DNA binding domain (DBD) of HNF4a contains a “Zinc Finger” motif coordinating two 
zinc ions for each monomer (Figure 5) spanning amino acids 50-120. Not only is the DNA 
binding domain responsible for the binding of the HNF4a homodimer to DNA, but it is also 
responsible in part for dimerization on DNA (75).
Figure 5: Stereo view of the crystal structure of the HNF4a DBD (PDB code: 3cbb) (16). Blue double 
helix: DNA. Red, blue, green and yellow ribbons: DNA binding protein chains of HNF4ot. Orange space­
fill balls: Zinc ions.
The DBD is found towards the N-terminus of the sequence (Figure 3); its presence along with 
the LBD defines H NF4a as a member of the nuclear receptor family. Out of all mammalian 
nuclear receptors HNF4a is most similar in sequence to RX Ra particularly in the DBD; it 
also shares many of the same response elements at several different genes and a consensus 
DR1 (77) ( direct repeat with a separation of 1 nucleotide) site of AGGTCA (18).
The DBD is phosphorylated in a number of places. One position is at the conserved Ser78 
which was shown to impair DNA binding and transactivation. This phosphorylation can 
result in the disruption of a near-by hydrophobic cluster causing the alteration of the structure
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displacing the helices and consequently affecting the complex’s binding to DNA. It is also 
thought to affect the conformation of the loop connecting the two main helices; these effects 
would also affect the contacts made by the DBD to DNA via Arg residues (Figure 6) (79). 
Truncation of the DNA binding domain (N-terminal) has little effect on the affinities of 
ligands that bind to HNF4a, compared to that of the full length HNF4a (20).
Figure 6: The HNF4a DBD (PDB code: 3cbb) showing the Arg and Lys residues (green) that contact 
DNA. a-helix: red, |3-sheet: yellow, loop: light blue.
Ligand binding domain (LBD)
The LBD or E domain (Figure 3) of HNF4a is responsible for more than just ligand binding. 
It is also responsible for dimerization with other HNF4a monomers and coregulators.
LBD
The overall structure of the E domain is very similar to that of other nuclear receptors; it 
contains the recognised LBD, the coregulator binding area and a dimerization interface. 
There are 9 -  10 a-helices and two (3-sheets making up a helical sandwich motif. Helices a-1 
and a-3 make the top layer, with helices a-4, a-5, a-8 and a-9  making up the central helical 
layer; helix a - 10 forms the bottom layer of the sandwich (Figure 7). Helix 2 is not present in 
HNF4al whereas it is in most other nuclear receptor LBDs, the a-6  helix is only one helical
Chapter 1 - Introduction
turn and helices a - 10 and a -1 1 are contiguous and is therefore referred to purely as helix a- 
10; the amino acid Pro333 causes a-10 to bend round the bulk of the E domain. Helix a-12 
appears in two conformations, in one state “the open state” helix 12 is fully extended and 
collinear with helix 10, however in the second state “the closed state” helix 12 is located 
against the body of the LBD (Figure 8). The hydrophobic residues Leu360, Leu361, Met364 
and Leu365 on helix 12 interact with some corresponding hydrophobic residues on the face 
of the LBD as part of helices a-3 (residues M etl82, Lysl83, Leul86, Leul87, Leul89 and 
Vall90) and a-4 (Leu211, Ala215, Gly216 and Leu219). This binding is aided by hydrogen 
bonds between Gln362 and Lys350 in helix a-10 and Glu363 and Arg212 in helix a-4, 
effectively anchoring the a-12 in place (27, 22).
Figure 7: HNF4a LBD helix numbering (21, 22) Image created using MOE (23).
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closed
Figure 8: Helices, shaded turquoise (al-ct9), yellow (alO), or red (a l2), reveal two distinct 
conformations: open on the left and closed on the right. (3 Strands are coloured green, the fatty acids in 
the ligand binding pockets are coloured magenta (21).
Ligand binding pocket
The ligand binding pocket (Figure 9) consists of predominantly hydrophobic residues from a 
number of different structural features, a3 (Ile l75, Vall78, Cysl79, M etl82), a5 (Leu219, 
Leu220, Ala223), ccl (Leu234, Leu236), (32 (Val242), loop 2/7 (Leu249), a7  (Met252, 
Val255, Ser256, Ile259), and alO  (Met342, Gln345, Ile346, Ile349). Both oxygens on the 
fatty acid head of the ligand are ion paired with the side chain of Arg226. Additional 
hydrogen bonds with the backbone NH on the Gly237 and the OH of Seri 81 are formed with 
one of the oxygens. The ligand takes up most of the volume of the pocket (370 A3) and is 
atypically (for a nuclear receptor) relatively linear, as is the ligand. The ligand is prevented 
from forming a U shape in the pocket by the residues M etl82 and Met342, which fill the top 
portion of the pocket. These residues are unique to HNF4a as a nuclear receptor (21).
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Figure 9: Stereo view of the fatty acid ligand (Space fill) in its pocket. Ribbon colours as in Figure 7. 
Image created using MOE (23).
HNF4a ligands
Ligands for HNF4a are generally accepted to be long-chain fatty acids (LCFAs) and long- 
chain fatty acyl-coenzyme As (LCFA-CoAs) (27, 22, 24-27). However, crystal structures of 
HNF4a published to date with a ligand bound to the binding site (27, 22, 24) show only a 
long chain fatty acid bound. This is most likely the result of the inherent instability of LCFA- 
CoA under the conditions in which the structures were crystallised, i.e. they degraded; but it 
was also shown that HNF4a significantly accelerated LCFA-CoA hydrolysis to LCFA by 
nearly 10 fold (27).
The sites for LCFA and LCFA-CoA have been shown to be distinct from each other as they 
appear to be specific to one or the other. It has been proposed that there is an element of 
crosstalk between the two sites. The ACS (Acyl-CoA binding Site) is thought to 
accommodate a LCFA-CoA in order to convert it to the LCFA via thioesterase activity and 
then pass it to the FAP (Fatty Acid Pocket) as a LCFA (Figure 10) (28).
- 11 -
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Figure 10: ACS/FAP crosstalk scheme showing the ACS (acyl-CoA binding site) and the FAP (Fatty acid 
binding pocket) where acyl-CoA binds to the ACS and is hydrolysed by ACS thioesterase activity, 
followed by the passing of the resultant fatty acid to the FAP. (28).
This has been shown to be the case, as the natural fatty acids that bind to the FAP have much 
lower affinities than their respective CoA analogues. Kd values for the fatty acids are 0.1 - 0.7 
pM implying relatively low affinities for the FAP however values for the fatty acyl-CoAs are 
around 0.4 -  4.0 nM suggesting high binding affinities of acyl-CoAs for the ACS (20, 25, 
28). Most ligands for HNF4a appear to have chain lengths over 12 carbons, however one of 
the most commonly found bound ligands appears to be C l6:1 (an unsaturated fat of 16 
carbons length (oleic acid)) with around 40 -  60 % of the entrapped fatty acids being of this 
type. This is despite low amounts of LCFAs found naturally in the expression system (E. coli 
bacterial extracts), however the acyl-CoA species of C16:l (C16:l-CoA) is apparently the 
dominant acyl-CoA species in E. coli bacterial extracts. This would appear to support the 
ACS/ FAP crosstalk theory (28).
The binding of LCFA-CoA (not LCFA) has been shown to alter the secondary structure, 
increasing the relative proportion of a-helices while decreasing the proportion of (3-sheets 
and turns. The lack of conformational change in the case of the LCFAs indicates that LCFAs 
are poor physiological ligands for HNF4a.
The removal of the F-domain results in the abolishment of any conformational 
responsiveness to ligands. In the light of this the F-domain is shown to be crucial for affinity 
and specificity of HNF4a for its ligands and to the conformational responsiveness to said 
ligands, along with their cooperation in dimerization upon ligand binding (20).
- 12-
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Co-regulators
Co-regulators can be thought of as “bridging molecules” which serve as communication 
between NRs and transcription machinery. They can act, depending on the co-regulator, as 
either activators or repressors. A co-activator (or transcriptional intermediary factor (TIF)) 
can mediate these interactions resulting in different information being communicated 
between the NR and the transcription machinery, dependant on the co-activator. Co­
repressors are able to interact with transcriptional activators, resulting in the inhibition of 
transcription (2).
HNF4a is known to interact with a number of co-regulating proteins to inhibit, mediate or 
enhance its activity. Some of the main co-regulators are given in Table 2:
Table 2: Main co-regulators known to interact with HNF4a
Name Action Reference
CBP Co-activator
Sladek (1999) Mol. Cell. Biol. 19, 6509
Yoshida (1997) Biochem. Biophys. Res. Commun. 241, 664
SRC1 Co-activator
Sladek (1999) Mol. Cell. Biol. 19, 6509 
W ang (1998) J. Biol. Chem. 273, 30847
PGC1 Co-activator
Yoon (2001) Nature 413,131 
Lin (2002) J. Biol. Chem. 277 ,1645
GRIP1 Co-activator
Sladek (1999) Mol. Cell. Biol. 19, 6509
Yoshida (1997) Biochem. Biophys. Res. Commun. 241, 664
MED1 Co-activator
M aeda (2002) Mol. Endocrinol. 16 ,1502  
Malik (2002) Mol. Cell. Biol. 22, 5626
NCOR2 Co-repressor R use (2002) Mol. Cell. Biol. 2 2 ,1 6 2 6
Dimerization interface
HNF4a is capable of only forming homodimers with itself (4). The crystallised structure of 
the rat form of HNF4a LBD (PDB code: lm7w) crystallises as a homodimer with 2-fold 
symmetry about the interface. This interface consists of a number of interactions: 
Hydrophobic side chain interactions: (Phe325:Phe325, Leu329:Leu329, Leu330:Ile283, 
Leu332:Leu330, Pro333:Pro333 and Trp340:Trp340); intermolecular salt bridges: 
(Glu269:Lys300, Arg303:Glu327 and Arg322:Asp312); hydrogen bonds: (Gln307:Glu327, 
Glu311:Gly323 and Gln336:Gln336) (27) (Figure 11). The residues that appear to be critical 
for homodimerization on DNA are Glu327 (helix-a-10) and Lys300 (helix-a-9), which are
- 13-
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reported to form a salt bridge between two HNF4a monomers. These two amino acids form a 
K(X)26E motif; which is reversed for RXRs and is thought to be the reason why RX Ra and 
HNF4a proteins cannot form heterodimers. However this motif, present in HNF4a, is also 
present in other species other than rat and in the P and y  forms, suggesting that they should be 
able to heterodimerize with each other (75).
Figure 11: Stereo view of the rat form HNF4a LBD (27), crystallised as a homodimer. Residues involved 
in the dimerization interface shown in space fill and coloured according to the ribbon colour (Figure 7). 
Image created using MOE (23).
The residues that play a role in dimerization in solution are Glu262 and Arg258 (helix-a-7) 
but they do not have a role in HNF4as dimerization on DNA. Removal of the carboxylic acid 
group at the Glu262 position will prevent necessary salt bridges and hydrogen bonds forming, 
resulting in strongly impaired dimerization. If the positive charge is removed at the Arg258 
position, this will reduce the dimerization potential to a greater extent than mutations 
observed for Glu262. Mutations at all three critical points at the dimerization interface: 
Glu262 & Arg258 for a-7  and Glu327 for a-10 were found to severely impair the ability of 
monomers to interact with each other. In order to assess the effect of Glu262 on the 
transcriptional activity of HNF4a, a series of substitution mutations were carried out; this had 
little effect, however deletion of Glu262 from the sequence resulted in the loss of 
transcription, as did the deletion of the neighbouring residue Asp261. An isoform of HNF4a2 
with Glu262 deleted was created to see if it had a dominant-negative effect on the wild type 
(WT) protein, this however was not the case. Further insight was sought by applying
- 14-
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mutations to a previously known dominant-negative: HNF4a without the AF-2 domain, this 
exhibits the dominant-negative effect through its ability to dimerise with the WT.HNF4a 
missing the AF-2 domain. This mutation reduced the activity of WT by 50%, but only 
reduced the HNF4a with Glu262 mutated to Ala by 29% and HNF4a with Glu262 mutated 
to Lys; by 26%. It was also found that a mutated dominant negative (HNF4a missing AF-2 
and Glu262 mutated to Ala) was only able to reduce the transcriptional activity of the WT by 
30% compared to the standard dominant-negative (50%). Glu262 is also required for the 
recruitment of coactivating proteins (SCR-la, p300, PGC-1 and COUP-TFII). Deletion, but 
not mutation of this residue, results in an impairment of the interaction with these 
coactivators. Overall the main core of the dimerization interface essential for dimerization on 
DNA, are helices a-9 & a -10; whereas helix a-7 is crucial for dimerization in solution (29). 
Mutational analysis of Asp261->Asn261, Glu269->Gln269, Gln307->Leu307, Asp312- 
>Asn312, Gln336->Leu336 and Arg324->Leu324 revealed no change in the ability of the 
mutants to homodimerize on DNA. The Arg324->Leu324 mutant was expected to destabilize 
dimerization as a result of the loss of an interaction between Arg324 and Glu276, this 
however was not the case. All the above mutants were also able to heterodimerize with the 
wild-type; all mutants were able to heterodimerize with the wild-type in solution.
The effect of the mutants on the transcriptional activity was also investigated. For mutants 
Asp261->Asn261, Glu269->Gln269, Gln307->Leu307, Asp312->Asn312 and Gln336- 
>Leu336 there was no effect, however Arg324->Leu324 abolished transcriptional activity 
thus impairing HNF4a activity. The ability of the mutants to interact with coactivators was 
looked into; Asp261->Asn261, Glu269->Gln269, Gln307->Leu307, Asp312->Asn312 and 
Gln336->Leu336 were found to retain the ability to further increase the transcriptional 
activity in the presence of PGC-1. The Arg324->Leu324 mutation was observed to not 
restore the transactivation potential in the presence of PGC-1 however there were still 
interactions with the coactivator. Comparison of this mutant with another known mutant at 
the 324 position was performed; the Arg324->His324 mutation had previously been recorded 
not to have an effect on HNF4a activity, the drastic nature of the Arg324->Leu324 mutation 
opposed to the Arg324->His324 mutation was attributed to the ability of the Leu mutation to 
eliminate the activity (30).
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AF-2 domain
The AF-2 domain (helix a -12) spans the amino acid residues 360-368 and is located at the 
end of the LBD. In the “closed state” the helix is collinear with helix a-10 (Figure 8); 
however when a ligand binds to the putative ligand binding domain, a conformational change 
is brought about such that the conformation of the contiguous helices a-10 and a -12 is 
changed whereby helix a -12 folds over the LBD and traps the ligand in place without 
actually interacting with it (27, 22). This is then locked in place by a coregulating protein 
with the motif LXXLL (L = Leu, X = any amino acid), a charge clamp is formed using 
Glu363 residue of a -12 and Lysl94 of a-3 (22).
The AF-2 domain is involved with a number of different proteins, for the most part 
interacting with coregulating proteins such as PGC-1 (31), it also interacts with other proteins 
such as the tumour suppressor p53, an interaction that results in the repression of HNF4a via 
the recruitment of Histone Deacetylases (32), and its resulting down regulation (33). HNF4a 
has been reported to interact with HNFla via the AF-2 domain and other residues in such a 
way as to enhance its mediated activation of transcription (34).
F-domain
The F domain is found at the C-terminus of the HNF4a sequence (Figure 3) and is reported 
to contain repressive functionality and to have direct contact with the LBD (20). The 
repressive functionality of this region was found to be closely associated with the amino acids 
428-441 and 371-414 regions (20): Although no actual structure has been derived for this 
region there are similarities to features in another nuclear receptor, the progesterone receptor 
(PR). This came from the three-dimensional structure of the PR LBD that contained its 
repressor region including a beta strand that is fixed in position by another anti parallel 0- 
strand situated between helix 8 and 9 of the LBD (35). This is also indicated by the truncation 
of the F-domain of HNF4a reducing the proportion of (3-sheet, turn and unordered content. In 
silico modelling has also predicted that residues 428-441 might form a |3-sheet and that there 
may be two other short organised domains, these are thought to be an a-helix at residues 383- 
389 and a p-strand at 392-396 (75, 20, 36).
It has been shown that the F-domain is involved in ligand binding and specificity. Deletion of 
the regulatory F-domain results in a marked change in the binding affinities for LCFA-CoA, 
these affinities were reduced 52-243 fold whereas affinities for LCFAs were increased by 4-
- 16 -
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52 fold. This indicates that deletion of the F domain has the net result of the specificity of 
HNF4a for the LCFA/ LCFA-CoA being greater for LCFA than for LCFA-CoA (20).
It is indicated that the truncation (removal of all amino acids not part of the LBD) required 
allowing the crystallization of the LBD leads to a change in the overall structure; the F- 
domain is reported to interact with the E-domain disrupting the helical components of the 
LBD causing an increase in the proportion of P-sheet formation. This deletion may also have 
reduced the size of the ligand binding pocket and the interactions between subunits. This 
indicates that the truncated forms crystallised to date may not represent the structure of the 
full-length receptor (20).
RXR
RXR (Retinoid X Receptor) is a member of the NR superfamily which is very similar to 
HNF4a (Figure 2) (15); however, it (unlike HNF4a) has the capability to dimerize with itself 
and numerous NRs including PPARs (15, 37, 38) and maintains the same overall structure as 
other NRs (Figure 3). There are three different isoforms of the RXR form: a, p and j .  Each 
isoform is expressed in different ways, RXRa is found in the kidneys, liver, spleen epidermis 
and placenta; RXRy in the brain and muscle and RXRP is found in all throughout the 
organism (38). It was RXRa, that was the first structure of a NR LBD to be solved (37, 39). 
RXR, like most other NRs, binds with ligands, the most common of which is 9-cis retinoic 
acid (39).
RXR is reported to bind to DNA in a number of different ways including as a DR1 as a 
homodimer, or as a palendromic repeat (Pal) or DR4 as a heterodimer (2, 17).
Structure availability for homology modelling
There are four structures of HNF4a fragments available; the crystal structure of the human 
HNF4a DBD was crystallized in 2008 by Lu et al. PDB code: 3cbb (resolution: 2.0 A) (16). 
The other three (PDB codes: lm7w, lpzl and 3fsl) are all of the LBD; the first of which was 
that of the rat HNF4a LBD, by Dhe-Paganon et al. 2002; and consisted of two homodimers 
of two monomers with a fatty acid bound to the ligand binding domain, PBD code: lm7w 
(resolution: 2.8 A) (21). Later a structure of the human HNF4a LBD was crystallized as a 
single monomer, by Duda et al. 2004. This included a fragment of a bound coactivator, PDB 
code: lpzl (resolution: 2.1 A) (22). In December 2009, after the modelling for this project had 
been completed, another more complete structure of the human HNF4a LBD was published
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by Rha et al. It included the section following the first helix that was missing from the 
previous two structures, PDB code: 3fsl (resolution: 2.2 A) (40).
ATP Synthase
ATP Synthase is used to provide energy via the conversion of adenosine diphosphate (ADP) 
into adenosine triphosphate (ATP) (Equation 1).
ADP + Pi(phosphate) <-> ATP 
Equation 1
ATP is often described as the “energy currency” (41-43) for biological systems, and is 
produced in large quantities. The importance of ATP synthase is underlined by the estimate 
that an active graduate student produces more than his or her own body weight in ATP in a 
day (44). The mechanism by which this conversion takes place is unique as it employs a 
biological rotor driven by the passage of protons through a membrane (44).
The ATP Synthase complex is constructed of numerous subunits that work together. The a  
and p units contain the catalytic sites that carry out the reaction between ADP and ATP; they 
are arranged in alternating a  and p units totalling three of each. In the centre of this structure 
is the central stalk which consists of a y unit with (in the case of mitochondrial ATP 
Synthase) 8 and 8 units at the “foot”, the arrangement is slightly different in the case of E. 
coli ATP Synthase (Figure 12). This “foot” is in contact with the c-ring, made up of 9 -  12 c- 
subunits in a ring formation. The c-ring and central stalk rotate with in the a  and p construct 
in order to cause the conformational changes required for catalytic activity. This rotation is a 
result of proton transport facilitated by the a-subunit that allows access to a proton (H+). This 
binds to a hydrophilic channel between the c-ring and the a-subunit and the ring moves round 
exposing an empty site for the next H+. The H+ stays bound to the c-ring until it has travelled 
nearly full circle back to the a-subunit where it enters a second hydrophilic channel that 
opens inside, whereupon it is released leaving an empty site for the next H+ (45).
The top of the structure (a P and y complex) is known as the FI domain and the c-ring, the a- 
unit and the other transmembrane units are known as the Fo domain (46). The Fo domain is 
where the antibiotic oligomycin binds inhibiting the production of ATP. Mutational studies 
have been performed revealing a possible binding site with in the F0 at the interface between 
the stationary a-subunit and the c-ring (47,48).
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Figure 12: Subunit arrangement for E. coli ATP Synthase, and passage of protons through the membrane
(49).
ADP + Pj
ATP synthase in different organisms
ATP synthase occurs in all organisms that form or cleave ATP coupled to proton 
translocation (44). Some of the most studied are those of: plant, yeast, bovine heart 
mitochondria and E. coli. The structures of the different types from different organisms vary 
in both their sequence and the number of subunits that go to make up the individual 
complexes (44, 46, 50). Figure 13 shows how mitochondrial ATP synthase differs from that
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of E. Coli, the mitochondrial form includes an F6-unit and a d-unit; it also illustrates how 
some of the equivalent subunits are assigned different names.
Matrix
Intermembrane space
Mitochondrial ATP Synthase £  coli ATP Synthase
Figure 13: Subunit arrangement and naming assignment of ATP synthase in mitochondria vs E. coli. 
Image adapted from http://rpi.edu/dept/bcbp/molbiochem/MBWeb/mbl/part2/flfo.htm (19/07/10)
Types of ATP synthase
ATP synthases evolved from a common ancestor and structural and functional changes have 
lead to the evolution of three distinct classes of ATP synthase enzyme with in eukaryotes, 
bacteria and archaea: A-type ATPase (A-ATPase), V-type ATPase (V-ATPase) and F-type 
ATPase (F-ATPase). The number of subunits for each depends on the organism they inhabit. 
For A-ATPase 12 to 4 subunits may be present; the simplest form of bacterial F-ATPase 
comprises only 8 different subunits, however the more complex beef heart mitochondrial F- 
ATPase contains 16 different subunits. Both these types synthesise ATP via the 
transformation of energy from an ion gradient across a membrane. The V(Vacuolar)-type (V- 
ATPase) is genetically similar to the F-ATPase, with at least 13 subunits, it is required for a 
variety of different cellular processes including bone reabsorption, neurotransmitter 
accumulation and activation of acid hydrolases (50). This thesis concentrates on the E. coli F- 
ATPase.
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The ATP synthase F0 domain, structure and mechanism of proton 
translocation
The Fo domain of the ATP synthase enzyme is constructed of numerous subunits; the main 
proton translocating subunits are the c-unit hair-pin helices that comprise the ring, and the 
stationary subunit-a.
Subunit-a
Subunit-a is the stationary module of the ATP synthase F0 domain responsible for proton 
translocation. With in subunit-a, a proton channel exists (Figure 14) carrying protons down to 
Arg210; which is responsible for transferring the proton to Asp61 on the c-unit (49, 51-54).
Figure 14: Proton channel through the stationary subunit-a of ATP synthase. A: Cross-sectional view of 
TMH2-5 of subunit-a depicted as a-helical wheels. The light green area on «TMH4 represents the helical 
face that crosslinks to TMH2 of subunit c. B: 3D model of subunit-a, with proton translating residues 
labelled. White arrows show a generalised proton path through the channel to the Arg210. Image 
modified from (55).
The c-ring
The c-ring is comprised of 9-14 (44, 56) hair-pin transmembrane helices depending on the 
form of ATP synthase (57, 58), arranged in a ring (Figure 15). The overall conformation of 
the individual c-unit depends on the protonation of the residue (in the case of E. coli) A sp61 
(Figure 16) which carries the proton round the ring during transport (53, 54, 59). This
A
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protonation takes place at the interface between the c-ring and the a-unit where the proton is 
transferred from the a-unit to Asp61 on the outer helix of the hair pin where it resides until it 
has come almost full circle, whereupon it is transferred back to the a-unit.
Subunit-a c-ring Subunit-a c-ring
Side view View from cytoplasm (top view)
Figure 15: Organisation of individual c-units (ring shape) and subunit-a in the F0 c ring of E. coli. (PDB 
code lc l7  (53)). Visualised using Accerlyls DS Visualizer (60).
s  * *>
+ -rx £
* 7  7 7  
c
N N
pH 8 pH 5
Figure 16: Differing conformations of the individual c-units that comprise the F0 c-ring of E. coli (Figure 
15) at different pH. Green: pH 8 (Asp 61 not protonated), Yellow: pH 5 (Asp 61 protonated) (53).
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Fo rotation mechanism
The general mechanism is described above in the introduction to this section, here a 
discussion of the mechanism for the transfer of the proton from subunit-a to the c-ring is 
presented. There has been much discussion on how the mechanism of rotation takes place at 
an atomic scale (49, 51-54).
The first mechanism proposed was by Vik & Antonio 1994. This suggested a four step 
progression (Figure 17) utilising a counter clockwise rotation of the c-ring via protonation 
from the periplasm, of Asp61 of the c-ring which is ion-paired with Arg210 on subunit-a 
(Figure 17 A). This protonation of Asp61 weakens the a-c interaction allowing the 
unprotonated Asp61 to rotate towards Arg210. The hydrogen bond between Glu219 and 
Asp61 is broken freeing Glu219, allowing it to deprotonate forming a H30+ ion (Figure 17
B). A new hydrogen bond is formed between Glu219 and the next Asp61 that rotates into its 
vicinity, meanwhile the H30+ ion protonates His245 (Figure 17 C). His245 then deprotonates 
to the cytoplasm thus returning the complex to the starting state (Figure 17 D) (54).
Rastogi & Girvin 1999 later published a mechanism (Figure 18), based on their model of the 
Fo domain including both the subunit-a and the c-ring (PDB code: lcl7). The complex starts 
off in a “resting state”; (Figure 18 A) where the Arg210 lies between both the deprotonated 
and protonated conformations of the c-hairpins (green and yellow respectively). Figure 18 B: 
The deprotonated conformation is protonated (green) and the Asp61 rotates towards its 
protonated conformation. Figure 18 C: “Fully protonated intermediate” where the ring has 
rotated by 30° with respect to subunit-a, and the Arg210 is once again resting between the two 
c-units. Figure 18 D: The proton on the blue c-unit is then lost to the proton channel on the 
cytoplasmic side of the membrane, causing it to adopt the deprotonated c-unit conformation 
and thus regenerating the overall “resting state” of the complex (53).
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Figure 17: Model of proton pathways in the ATP synthase F0 (54) , mechanism discussed in the text.
- 24 -
Chapter 1 - Introduction
C19 oligomer
A
Subunit e
Subunit a
X  ^
Figure 18: Mechanism of the rotation of the c-ring with respect to subunit-a as published by Rastogi & 
Girvin 1999 (53). Mechanism discussed in the text.
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The mechanism proposed by Rastogi & Girvin 1999 was later adapted by Fillingame et al. 
2002 (51, 52) and Aksimentiev et al. 2004 (Figure 19) (49).
a4
e)
d )
UT-
f)
Figure 19: Adapted mechanism of the rotation of the c-ring with respect to subunit-a as published by 
Aksimentiev et al. 2004 (49). See text for a description of the steps a-f.
The starting conformation of the complex described here begins with the two Asp61 residues 
on the c-units (c2L & c2R) being deprotonated, forming a bidentate salt bridge with the
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Arg210 of subunit-a (Figure 19 a). The Asp61 of c2R is then protonated by Asn214 of the 
periplasmic proton channel with in subunit-a (Figure 19 b). Subunit-a rotates as the c-ring 
turns bringing with it the deprotonated Asp61 of c 2l , while the Asp61 of c2L’ rotates either 
clockwise or anticlockwise by 180° (Figure 19 c) resulting in Figure 19 d. The Asp61 of c2l’ 
deprotonates, donating its H+ to the Ser206 of the cytoplasmic proton channel with in 
subunit-a (Figure 19 e). The system has then rotated by one c-unit round to the starting 
position as depicted in Figure 19 a (Figure 19 f) (49).
Oligomycin
Oligomycin is created by a species of bacteria known as Streptomyces which are responsible 
for the production of a great deal of the clinically useful antibiotics (61). Oligomycin is 
generally a mixture of three different types A, B and C (Figure 20) at a ratio of 75:10:8 as 
determined by HPLC (62). Their molecular weights are 821.09 g/mol, 863.01 g/mol and 
775.08 g/mol for A, B and C respectively. The structures of the three individual forms are 
slightly different. The structure of oligomycin A and its acetylated derivative as characterized 
by NMR, has been published (63, 64) and the structures of the B and C forms are also 
published using X-ray and NMR data for B (65, 66) and just NMR for C (66). The structure 
of a close relative, rutamycin has been characterized by X-ray crystallography (67), however 
there was until recently no published X-ray structure of oligomycin A. An X-ray structure of 
oligomycin A has been obtained (68)\ however there appears to be an anomaly in the 
geometry of a particular group on the structure. This anomaly is discussed and investigated in 
the chapter “Inhibition of ATP Synthase: The binding of oligomycin”.
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A
Figure 20: The three forms of oligomycin as crystallised. Solvent crystallized with the A and B forms, 
methanol and ethanoic acid respectively. (68)
Oligomycin A has been the subject of some investigation with respect to its ability to form 
complexes with mono and divalent cations (62, 69). It was shown that the smaller 
monovalent cations Li+ and Na+ were almost completely isolated from the environment, Li+ 
was more isolated due to its small size (62). Given this, it would be reasonable to speculate 
that the coordination with and isolation of Na+; would likely have an additive effect when 
inhibiting Na+ transporting ATP synthase. Complexes involving divalent metals are generally 
stabilised by association with an anion (69).
Oligomycin and ATP synthase
Oligomycin has long been known to be an inhibitor of the ATP synthase complex (70). 
Mutational analysis of subunit-a and c-units, with a view to identifying residues that inhibit 
oligomycin binding; has been carried out in order to locate the binding site of oligomycin. 
Mutations carried out on the yeast mitochondrial ATP synthase (48, 71) revealed that the 
binding site for oligomycin is likely to rest between the stationary subunit-a and the hairpin 
(47, 72). On the c-unit the area that was shown to display oligomycin resistance centres on 
the amino acid positions 23 and 59 (48), Glu59 is the equivalent to the proton translocating 
residue Asp61 in E. coli (Figure 21) (42, 48). Amino acid substitutions with in subunit-a, in 
the region of the proton channel (Figure 14) have been shown to result in cells being 
oligomycin resistant (73).
A computational model of the Mycobacterium tuberculosis ATP synthase based on the model 
of E. coli published by Rastogi & Girvin 1999 (53) was built by de Jonge et al. 2007, in 
order to bind a new drug candidate. The binding site to which the compound was targeted,
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was a grid cell of volume 32A x 32A x 32A; centred on the conserved Glu61 (Asp61 in E. 
coli) (59).
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Figure 21: A: Intra-membrane domains of drug resistance of subunit 9 in yeast mtATPase. The 
membrane domains of resistance to either oligomycin (thin lines) or to both oligomycin and venturicidin 
(thick lines) (48). B: Alignment of the yeast mtATPase c-unit sequence with that of E. coli, adapted from 
(42), shows conserved areas including the equivalence of Asp61 (E. coli) and Glu59 (yeast mtATPase).
As mentioned previously, oligomycin is known to inhibit ATP synthase. Inhibition is not 
limited to one type of ATP synthase and has also been used to inhibit; mitochondrial (48, 71, 
74, 75), bacterial (including E. coli) (75-77) and chloroplast (75, 78) ATP synthases. It is 
widely accepted that oligomycin inhibits the Fo domain by preventing H+ transport across the 
membrane in which, the Fo domain resides.
Binding constants (Ki) for the binding of oligomycin have been obtained for a number of 
ATP synthase types. ATP synthase in submitochondrial particles was reported to be 
“exquisitely sensitive” to oligomycin (Ki ~ 3x1 O'7 M (0.3pM)) (79). Bovine heart 
mitochondrial ATP synthase was shown to have a Ki range of between 0. l|iM  - 0.6pM (80).
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Mg+-ATP synthase in membranes of growth hormone and prolactin secretory granules was 
shown to be potently inhibited with a Ki = 6.5x1 O'9 M, with pituitary mitochondrial ATP 
synthase being inhibited with a Ki = 2.7x10‘7 M(81).
Structure availability for homology modelling
There are a number of different structures available of the individual c and a subunits that 
comprise the Fo domain of ATP synthase. The only full structure of subunit-a in combination 
with the c-ring was published by Rastogi & Girvin in 1999, this structure is a model 
constructed from NMR data in combination with cystine cross-linking data and simulated 
annealing calculations (53). This model was used and modified via homology modelling in 
the creation of a suitable model for the docking of a drug candidate to the Mycobacterium 
tuberculosis form of ATP synthase (59).
Homology modelling
Homology modelling is a method where by the structure of a protein is modelled on known 
structures derived from experimental data such as NMR or X-ray diffraction. The amino acid 
sequence of the structure to be modelled is aligned with that of a known structure. Generally 
differing amino acids in the known structure are replaced with those of the unknown 
sequence, and an energy minimization is performed to relax the system.
Homology modelling used in this work is discussed in more detail the chapter 
“Computational theory”.
The “lock and key” theory of protein-drug interaction
An underlying principle of how drugs and ligands interact with proteins is widely known as 
the “lock and key” theory, first postulated by Emil Fischer in 1894. The basis of the 
hypothesis is that a ligand has to fit into the protein binding site, much like a key fits a lock 
(Figure 22) in order to elicit a response (82). This response could occur in a number of ways, 
for example it could induce a chemical reaction where the ligand is changed either by the 
cleavage of a group from itself or another molecule; binding of the ligand could also cause a 
conformational to the protein allowing or preventing binding by another ligand or protein. 
The possibilities of the resultant reaction have the potential to be wide and varied.
Owing to the huge variation in the number of different ways a ligand may interact with a 
protein it was necessary to modify the original hypothesis. In 1958; Koshland introduced the
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“induced fit” theory where the ligand and protein act as “hand in glove”, i.e. the ligand and 
binding site both adjust their shape to accommodate each other (Figure 22) (82).
Figure 22: A: Lock and key. B: Induced fit
This theory is the basis of the idea of protein-ligand docking. Protein-ligand docking is a 
computational technique where by a ligand is associated with a protein binding site. Usually 
the ligand is considered flexible and is “docked” in a number of conformations to a rigid 
protein structure, though with the increase of computational power, it is becoming possible to 
dock ligands to a flexible pocket with in the protein; where the sidechains are flexible, or to a 
number of static conformations of the same protein (83).
The method for docking used for this work is discussed in the chapter “Computational 
theory”.
Aims for the modelling of HNF4cc
In order to further the understanding of HNF4a, its structure and function; homology 
modelling and molecular dynamics are used to build as complete a model of the HN F4a 
structure as is currently possible with the available structural information. This will result in a 
model of a truncated structure including the DBD and LBD, but lacking the AF-1 domain and 
the F-domain. The model will then be analysed to derive interactions between two H N F4a 
monomers. This has the potential to highlight important interactions; such as those involving 
mutations involved in diabetes, and any previously unseen interactions that could be 
significant with respect to how the complex functions.
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Aims for the modelling of the ATP synthase Fo domain and its interaction with 
oligomycin
The aim of this work is to investigate the structures of the antibiotic oligomycin recently 
crystallized by Palmer and Potter in 2008. The x-ray crystal structures of the three forms of 
oligomycin (A, B and C) (68) will be used as the starting conformations to be docked into the 
oligomycin binding site of ATP synthase, located at the interface between the stationary 
subunit a and the rotating c-ring where proton translocation occurs (49, 51-54).
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Computational Theory
A range of computational modelling techniques and tools are used in the research presented here. 
All calculations (unless otherwise stated) used in this work were performed using MOE 
(Molecular Operating Environment) (1), in this section the theory employed behind these 
calculations is covered.
The software and hardware used to perform calculations and modelling is as follows:
MOE (Molecular Operating Environment) 2006.07 (1): A  powerful program that brings 
together a number of techniques and programs to facilitate easy viewing, analysis and 
manipulation of chemical data, including small molecules, proteins, ligand - protein interactions, 
homology modelling, sequence alignment and energy minimization.
Programs and algorithms used by this suit include:
AMBER99 (1): molecular mechanics based algorithm for the modelling of large molecules such 
as proteins.
Blosuml00/62 (2): an algorithm used to align protein sequences.
Other programs that have been developed specifically for MOE include a Site Finder program 
that determines likely ligand binding sites on the surface of a protein.
Gaussian 03 (3) + GaussView (4): used to visualize (GaussView) and perform molecular orbital 
and ab-initio calculations on small molecules.
SWISSMODEL (5, 6): An automated protein modelling server: builds models based on 
structures with similar amino acid sequences.
The system that most calculations (apart from SWISSMODEL) were run on was a Dell Precision 
PWS390 computer with the following specification:
• Intel ® Core™ 2 CPU 6300 1.86GHz
• 2.00 GB RAM
• 148 GB Hard Disc
Molecular dynamics calculations were run on a Dell Optiplex 755 computer with the 
specification:
• Intel ® Core™ Quad CPU Q6700 2.66GHz
• 3.50 GB RAM
• 2 x 232 GB Hard Disc
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Energy minimization
Energy minimization (also known as geometry optimization) techniques are used to minimize the 
potential energy of a molecule. This is basically done by moving the atoms in a molecule so that 
they are in their most favoured geometries while allowing the defined bonds to remain intact. 
This is used to relieve “strain”, reduce atom clashes (where atoms inhabit the same space) and 
having structures at a minimum energy can be useful if one is comparing similar systems. 
Different conformations of the same molecule have different energies associated with them. The 
energy of the molecule will change with the torsional rotation of a functional group, the 
stretching or compressing of bonds or the bending of an angle: this gives a potential energy 
surface for all the geometries that the molecule could adopt. This energy surface increases in size 
with greater possible numbers of potential geometries. Energy minimization techniques are a 
search of this energy surface in order to find the lowest possible energy conformation. On 
occasion the output of the technique will be a conformation that is plainly not possible, or result 
in a high energy structure; i.e. extreme bond lengths, angles and atoms occupying the same space. 
In such a situation the technique is most likely to have found a “local minimum”. This is where 
the algorithm has found a pocket with in the energy surface and was unable to move from that 
pocket. Solving this issue is generally a case of changing the position of the atoms and remnning 
the calculation, thus giving the calculation a new starting point from which it may find the lowest 
possible energy conformation or “global minimum”.
MOE employs two methods for energy minimization: Quantum mechanical optimization (not 
used in this work) and force field optimization. The force field optimization used by MOE 
implements a non-linear optimization algorithm, shown here:
Xk = vector of atomic coordinates at step k 
U = energy function
1. Test for convergence. If all three of the following conditions (A, B & C) are satisfied Xk is 
returned. (T: a predefined constant representing the number of significant figures in U required, 
this is essentially a limit set by the user as to how accurately the calculation is solved)
A) Root mean square gradient test: Igrad U(x*)l < eA sqrt(n) 
eA - a predefined constant 
n = the number of unfixed atoms
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B) Iteration Limit Test: k > K
K =  a predefined upper limit on the number of iterations
C) Progress Tests: all three of the following conditions are met simultaneously:
U(xk.x) - U(xk) < T (  1 + \U(xk)\)
\xk.i-x k\ < T m (1 + bftl)
Igrad U(xk)I <= Tm (1 + \U(xk)\)
2. Compute the search direction. A non-zero vector: pk = search direction.
3. Compute the step size. A non-zero scalar called the step size is computed: ak where
U(xk + akpk) < U(xk).
4. Advance. Set = xk and k = k + 1 and go to Step 1.
For the calculation of the search direction; MOE uses a set of three methods to achieve a result: 
Steepest descent (SD), Conjugate gradient (CG) and Truncated Newton (TN).
Steepest descent method
To find a minimum of the energy surface, the steepest descent algorithm will perform a series of 
function evaluations in the direction of the negative gradient. Once the function begins to 
increase (i.e. the algorithm has passed the minimum) a rough minimum may be interpolated 
between the calculated points, at this point the algorithm then recalculates the gradient, and this 
new gradient is then used for the next line search.
The steepest descent algorithm has been described as “sure-fire” because if the line minimization 
is carried out with sufficient accuracy, it will always lower the value of the function; thus it is 
guaranteed to approach a minimum. However, there are some problems associated with this type 
of search:
a) The path of the steepest descent algorithm will oscillate around the minimum: this is not ideal 
particularly for surfaces with long narrow valleys.
b) As the algorithm progresses towards a minimum, the rate of convergence slows down; i.e. it 
will never actually reach the minimum but it will progress toward it increasingly slowly.
-44-
Chapter 2 -  Computational Theory
c) Owing to the perpendicular nature of each line search in relation to each other (i.e. the second 
line search will be at right angles to the first) the first direction might have been progressing in 
the required direction of the negative gradient. However the second line search will not follow 
the same line and thus there will be a tendency to partly “spoil” the progress made by the first.
On the other hand this algorithm is very simple and only requires the storage of the gradient 
vector, and as previously stated it is one of the few methods that will guarantee that the value of 
the function will be lowered (7).
Conjugate gradient method
The conjugate gradient method is similar to the steepest descent method; it differs by trying to 
overcome the issue where the method may take a direction that will partly “spoil” the algorithms 
progress. It does this by choosing a direction that is “conjugate” to the previous search direction, 
between the negative gradient and the direction of the previous search (7, 8). Figure 23 shows the 
search patterns associated with both the steepest descent and conjugate gradient methods.
Figure 23: Illustration of the energy minimisation search of the steepest descent method (green) and the 
conjugate gradient method (red) from the starting point (X0) to the minimum (X).
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Truncated Newton method
The Truncated Newton method used by MOE (9) is implemented when the gradient has been 
sufficiently lowered by the preceding conjugate gradient method. The Newton-Raphson method 
on which it is based can be used to locate either the roots of an equation or stationary points close 
to the initial starting point (7). According to the MOE manual, “The Truncated Newton method 
attempts to use curvature information to improve convergence.” (7). To find stationary points 
(local and hopefully global minima), Equation 2 is used:
X  m =  X  —/2 + 1  n
f \ * n ) 
/ " ( * „ )  
Equation 2
x„ = sequence of iterations (xo = the initial guess).
MOE uses the form:
Gk (xk)p  = - g r a d U ( x k)
Equation 3: (9)
p  = xn+j-xn = search direction
- g r a d ^ l = - I ^ -  
Gk(xk) f" (xn)
G being the second derivative of U.
An iterative linear equation solver based on the linear conjugate gradient method is used and is 
stopped after a small number of iterations therefore “truncating” the calculation, thus giving rise 
to the name Truncated Newton (9).
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The AMBER Force Field
Owing to the size of the systems associated with modelling proteins, it is not yet possible to carry 
out large scale calculations for energies, interactions or geometrical optimizations using ab-initio 
or semi-empirical molecular orbital calculations. Instead molecular mechanics force fields are 
used. These use a collection of geometric terms including bond lengths, angles, torsions and their 
associated force constants (Equation 4 and Figure 24). X-ray crystallographic data have been 
used as a basis for bond lengths and the force constants are generally derived from vibrational 
spectroscopy and molecular orbital calculations performed on small molecules (10).
AMBER is a well known and widely used force field for the modelling of proteins and peptides, 
although not the only force field parameters available in MOE (9). The specific generation of 
AMBER parameters used here were from the AMBER99 force field (11).
The general AMBER force field equation is as follows (5, 10, 11):
fp a ir — ^  '  k f( r  — req)2 4- y  K&(0 — 9 0qf  4-
bonds angles
E  ~ [1  + COs(/70 — y)j -I- E
dihedrals i < j
Equation 4
Stretch (bond length)
Bend (Angle)
Non-bonded interaction
Torsion
Figure 24: Illustration of the basic force field energy terms (Adapted from (7))
The first term in Equation 4 describes bond energies (Stretching (Figure 24)). 
Kr = force constant (kcal/ (mol A2)) 
r = bond length (A) 
req = the ideal bond length (A)
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The next term in Equation 4 describes angle strain (Bending (Figure 24)).
Kq-  force constant (kcal/ (mol radian2))
0 = bond angle (deg)
0eq = ideal bond angle (deg)
For these two terms; the bonds and angles are represented by a simple diagonal harmonic 
expression (10).
The third term deals with dihedrals (Torsion (Figure 24)).
Vn = barrier to rotation (Vn/2 = magnitude of torsion (kcal/mol)) 
n = periodicity of the torsion (describes the return of energy after a 360° rotation (8))
$ = torsion angle (deg)
y -  phase offset in degrees (0-180°)
The barrier to rotation, represented by Vn, can have different properties depending on the atoms 
involved in the torsional angle. There are three types defined: general, specific and improper. 
These are illustrated with examples as given by Weiner et al. 1984 (5).
The general parameter is applied to configurations such as (for example): the case of X- 
CH-CH-X, where V3/2 = 2.0 kcal/mol, with 4 bonds and y  = 0°. As CH has two non-hydrogen 
attachments, there are four X-CH-CH-X for each bond, and a torsional potential of magnitude of
0.5 kcal/mol, at y  = 0° hence V3/2 = 2.0 kcal/mol. This results in a preference for staggered 
conformation over the eclipsed (5).
The specific parameter overrides that of the general in all cases, this ensures that the 
gauche effect is observed for situations such as O-C-C-O where V3/2 = 0.5 kcal/mol and V2/2 =
0.5 kcal/mol. Another example of particular interest here, is that of the peptide bond where Vi/2 =
0.65 kcal/mol (5).
Improper torsions, such as C’-Ca-N-H for a peptide; have a large value assigned to V3/2 . 
This is the case where there are four atoms that are not bonded in succession (5).
For situations where there is no or little experimental torsional data, a dual linear scaling method 
is employed; pure single bonds, pure double bonds and partial double bonds are used as reference 
points.
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The last term is for non-bonded interactions (see Figure 24). This is a combination of two terms; 
the first for van der Waal interactions (Lennard-Jones potential: Equation 5); and the second for 
electrostatic interactions (Coulombic Equation 6).
e = van der Waals well depth (minimum energy at the optimal distance between two 
atoms)
r* = distance between atoms at £ 
r = non-bonded distance
qi -  charge on atom i
qj = charge on atom j
8 = dielectric constant
rij = distance between atoms i and j
Equations 4 and 5 combine to give the term:
Equation 7: Energy of non-bonded interaction
Equation 5: Lennard-Jones potential
electrostatic
Equation 6: Coulombic potential
non-bonded
Where:
Ry =  Ri +  Rj =  nj =  n +  rj
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The distant dependant dielectric term (Equation 8) is used in this work to model the solvation of 
the model.
Equation 8
Where
W e i e  = a weighting
d = dielectric constant
qi -  partial charge on atom i
beie = a buffering constant preventing division by 0
/ le = an interaction scale factor, where / le = 0 for 1-2 and 1-3 interactions, a parameter 
set-dependent scaling value for 1-4 interactions and 1 for other interactions.
T = the interaction scale factor for the scaling specific non-bonded interactions
ij wild
Titnhlr£
if T, = Tj 
if Tt *  Tj and (T, = 0 or 7\ = 0)
unlike otherwise
s  = “smoothing” or cutoff function
1 V r <r0
s(r) = \ \ - p { { r - r 0) / ( i i - r 0)) if r e [r0, r j
0 i f  r > r 1
Such that:
p ( x )  =  x 3(6 x 2 -  15x + 10)
The polynomial has properties so that:
/>(D=1
P( 0) =  0
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pX0)=p'(l) = 0 
p"(0) = p"(l) = 0 .
Setting the cutoff parameters ro and n, a range of tapering functions are created (9).
Homology modelling
Homology modelling is a method of creating novel protein structures by aligning the unknown 
amino acid sequence with that of a known structure. The term homology derives from the Greek 
term meaning “to agree”. Before the models can be constructed, the relevant sequences must be 
aligned with suitable structures on which to base a resultant model. Two homology modelling 
methodologies were used in the construction of models in this work. Primarily the MOE 
homology modelling tool (9) was used to build models, the automated homology modelling 
server Swiss-Model (12) was also used.
Sequence alignment
Amino acid sequences used in this work were obtained from the European Bioinformatics 
Institute database located at http://www.ebi.ac.uk. and were loaded into MOE (9).
MOE uses an approach where the alignments are carried out using an optimizing function based 
on residue similarity scores and gap penalties; the similarity scores are obtained by applying an 
amino acid substitution matrix to pairs of aligned residues.
The methodology used in MOE is divided into four steps:
1. Initial pairwise build-up: This is the initial estimate of the alignment, and is 
performed in 1 of two ways:
a. Tree-based: The alignment score between each pair of chains is pre­
calculated and the chain is aligned with that with the highest pairwise score.
b. Progressive: Each chain is aligned according to the order the chains are 
presented in.
2. Round-robin realignment: A refinement of the initial alignment is performed by 
extracting each chain from the overall alignment and is re-aligned against the 
remaining chains.
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3. Randomized iterative refinement: Owing to sensitivity to the order in which chains 
are processed, a second refinement step is taken; where the group of aligned chains 
are randomly split into two groups and a two-way alignment of the two groups is 
carried out. Only if there is improvement on the previous alignment, is the result 
accepted.
4. Structure-based realignment: Although not used in this work, MOE contains the 
option to superpose the atomic coordinates of the a-carbons of those chains that have 
structures associated, after the initial alignment. This is done until the RMSD (root 
mean square deviation) fails to improve, these chains are then reintroduced and the 
first three steps are repeated.
Superposition
In some cases during modelling one protein structure will be overlaid on to another; this may be 
for the purposes of calculating the structural similarity, or to move a structure into a specific 
position in relation to another structure.
The RMSD (root mean squared deviation) is the measure of how structurally dissimilar protein 
structures are, the closer to OA the RMSD is, the more structurally similar the structures. 
Superposition in MOE is carried out on aligned sequences of protein structures. In order to 
optimize atomic coordinate superposition, MOE uses a method developed by Shapiro et al. (13), 
which uses the MSD (mean squared distance) and is given by (9):
M  N kl ■ ■
Z Z v« Z w ‘ K fo*- h ) - R i { x tt - 0 |
k=1 I>1 i=1
Where
M = number of proteins
Nu = number of corresponding atoms
Vki = protein-to-protein importance weights
Wj = importance weight of each atom correspondence
Rk and Ri = rotation matrices
xik = coordinates of the /th corresponding atom in the kth protein 
xu = coordinates of the z>th corresponding atom in the /th protein 
tk and ti = translation vectors
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Homology modelling in MOE
The homology modelling tool in MOE works in three steps.
1. Initial partial geometry specification: Coordinates of the backbone of the template 
that are conserved with those in the unknown sequence are aligned and copied (9).
2. Building the intermediate models: In this step lists of molecular data are collected; 
this is information that will be used to model the sections of the model not provided in 
the template, such as loops, insertions, and sidechains. Once these data are collected, a 
set of independent models is created based on this information. When all the parts of 
the model that were not copied from the template have been modelled, hydrogens are 
added in order to fill any valence requirements. This step is concluded with a series of 
energy minimizations that are designed to relive any serious steric strains and prepare 
the models for scoring (9).
3. Choosing and refining the final model: The final model is based on the best scoring 
intermediate model according to the electrostatic solvation energy which is calculated 
using a Generalised Bom/ Volume Integral method (9,14).
Swiss-Model
SWISS-MODEL is an automated protein modelling server (located at 
http://swissmodel.expasv.org/). based on comparative protein modelling (homology modelling). 
The server chooses structures on which to base a model through similarity of sequence from its 
protein structure database. Once templates for the model have been identified they are aligned 
using 3D superposition and the “target sequence” (that of the model to be generated) is then 
aligned with this alignment. This gives a spatial correspondence between the template structures 
and the target sequence providing a guideline for the model building procedure. Once this is 
accomplished, an average framework for the model is generated from the superimposed 
templates, and atomic coordinates are then generated. Non-conserved loops, including any 
required insertions and deletions, are then built based on structural homology with protein 
structures using the Brookhaven Data Bank. A library of backbone elements derived from X-ray 
crystal structures is then used to complete the main chain. Missing side-chains are constructed 
and correction of existing ones is carried out using a library of allowed rotamers.
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The resultant model is then assessed for its quality followed by energy minimization in order to 
optimize bond geometries and relieve unfavourable non-bonded contacts by 50 steps of steepest 
decent and then 500 steps of conjugate gradient. Confidence factors are also computed for each 
amino acid and added to the output file, which is then e-mailed to the user (15).
Validation
Validation of models of protein structure is done by examination of the structural geometry. One 
of the most common methods is the Ramachandran plot (16). This plots the backbone angles cp 
and \)/ (Figure 25) against each other, and compares it to a plot of these angles from experimental 
data gathered from x-ray crystal protein structures. If a model is considered to be a good model, 
the angles of the backbone from the model being validated will correspond to regions in the plot 
where the data from previously known structures, is gathered.
Figure 25: Backbone angle assignment.
For protein structure validation in MOE, there are some extra tools available which evaluate 
geometries such as backbone bond lengths, bond angles and torsions by comparing them to 
expected values (9).
Other factors that can be assessed include “atom clashes”. Non-hydrogen atoms are given a set 
radius in combination with a van der Waals optimal interaction energy and a distance-dependant 
function in order to provide a van der Waals repulsion energy. Parameters that are commonly 
used in crystallographic refinement were used for this function (repulsion well-depth and van der
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Waals’ radii) are those used in the Engh-Huber forcefield (17). The function used is w800(l-r/R), 
where w is the geometric mean of the well-depth parameters of the two atoms being observed, r 
is the interatomic separation distance and R is the sum of the van der Waals’ radii (9).
Docking
Protein ligand docking is a technique that allows a computational chemist to see how a drug 
might fit into a binding pocket. This is useful for a number of different reasons; it can highlight 
the essential residues in a binding site that are required for function and new drugs that bind 
better to the site may be designed based on an analysis of the groups on the ligand and how and 
where they interact with the protein.
The protein-ligand docking carried out here was performed using MOE (9), which uses the 
following methodology:
1. Conformational analysis: A brief conformational analysis is performed on the ligand by 
applying a set of preferred torsion angles to the any rotatable bonds. For large ligands a 
random sample of conformations are used, whereas for smaller ligands a systematic 
search of the conformational space is performed by generating all combinations of angles 
(9).
2. Placement: A set of poses is taken from the conformations previously generated and 
placed using a placement methodology: this methodology is described in the section 
“Ligand placement”.
3. Pharmacophore Filtering: An arbitrary pharmacophore is used to constrain the 
generated poses. This is an option in MOE’s docking application, but was not used in this 
work.
4. Scoring: To identify the most favourable poses a scoring function is used, in the case of 
this work, the London dG method is used: this is discussed in the section “Calculation of 
energies of bound ligands”.
Pocket Location
MOE uses a pocket locating tool called Site Finder; its purpose is “to calculate possible active 
sites in a receptor from the 3D atomic coordinates” (9). It is classed as a geometric method of
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finding pockets on a receptor, as no energy models are used. According to the MOE manual a 
rough classification of the receptor atoms and their accessibility and position is used in order to 
define a potential pocket.
The methodology uses a form of Delaunay triangulation to identify a collection of 3D points, 
each collection of four points have a sphere associated with them known as an alpha sphere 
whose radii range widely up to infinity. These collections are filtered based on the removal of 
those collections that are in inaccessible parts of the receptor or over exposed to solvent. Smaller 
spheres are kept as they correspond to tight atomic packing in the receptor. The alpha spheres are 
classified either hydrophilic or hydrophobic, based on their proximity to hydrogen bonding 
residues, and grouped to produce a collection of potential sites (9).
Ligand Placement
MOE uses a method of fitting the ligand to the binding site, called the Alpha Triangle method. 
This uses a random selection of three ligand atoms and matches them to a random selection of 
three centres (representing locations of tight packing) in order to settle on a pose for the ligand. 
These centres are those calculated by Site Finder (9).
Calculation of energies of bound ligands
Bound conformations are ranked according to the London dG scoring function. The London dG 
scoring function calculates an estimate of the free energy for a given pose using the following 
equation:
AG =  C +  Ejjm + ^ C HBf HB + CMfu  +
h-bonds m-llg atoms i
Equation 9: London dG scoring function for the estimation of free energy for a given pose (9).
c = average loss or gain of rotational and translational entropy.
E/iex = energy due to the loss of flexibility of the ligand as calculated from the ligand topology. 
fiiB -  measures geometric imperfections of H-bonds. 
chb-  ideal H-bond energy.
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f M = measures geometric imperfections of metal ligation. 
cm-  ideal metal energy.
Di = desolvation energy of atom i.
The change in the desolvation energy (AD,) is calculated using:
AD- = c}R? < \ u \~6 dui i t  i i u I"6 du >
Equation 10: formula used for the calculation of the change in desolvation energy (9).
A and B  = protein and/or ligand volumes with atom i belonging to volume B. 
d  = desolvation coefficient of atom /.
Ri = solvation radius of atom i.
cf chby cm, Ci were fitted from 400 X-ray crystal structures of protein ligand complexes with 
experimental pKi data.
Inhibition constant calculation
K\ (inhibition constant) values for docked conformations are calculated from AG (Gibbs free 
energy, the output value from the docking scoring method) (18):
K»=Kr
AG= —RT In Keq 
Ki =Kd =  1 /X eq 
AG= -RT  In l/Ki 
AG=RT In K\
Molecular dynamics
In computational chemistry, calculations and experiments are conducted at single points, i.e. in a 
rigid system. However this is not the case in the real world: molecules are in a constant state of 
movement and so to observe a system in movement molecular dynamics calculations can be 
performed. The simple definition of molecular dynamics is that it “simulates the motions of a
Ki = &1AG/RT
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system of particles (atoms) with respect to the forces which are present” (19). This is addressed 
by solving the classical equations of motion for a system of N  atoms, in order to perform a 
conformational search of the available space (otherwise known as a trajectory) with in the 
confines of thermodynamic conditions (9).
Newton’s second law is the basis of molecular dynamics:
Where F is the force acting on a particle (i) (or atom), m is the mass of the particle and a its 
acceleration, a can be written as the second derivative of s (the displacement experienced by the 
particle) with respect to time t:
Obtaining a dynamic system is accomplished by solving the second order differential equation for 
each atom in the system. Integration of Equation 12 with respect to time gives an expression for 
the velocity
When t = 0, hs/ht disappears and the velocity is given by c\, the initial velocity given as uL Thus 
at time t:
Equation 11
Equation 12
Equation 13
Equation 14
Therefore the expression for velocity at any time t is
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Equation 15
To calculate the displacement from the initial velocity ui, and the acceleration at (from at = 
Fi/rrii); Equation 15 is integrated with respect to time t to produce
Equation 16
where the constant C2 is the current position (19).
One of the most common methods used to implement this derivation is the truncated Taylor
However, owing to the truncated nature of this series, error is introduced at each time step (At), 
and the acceleration stays constant which means that small time steps (the order of 0.5-1 fs) must 
be taken. The trade off is that the smaller the time step; the greater amount of computation time is 
required (17).
To overcome the issues with truncation and small time steps a number of algorithms have been 
developed, one of the most commonly used is the Leapfrog Verlet method:
Where v is the average velocity over At, and the assumption that the velocity at the midpoint of
the time interval (/ + At) is almost equal to v:
senes:
Equation 17
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s(t  + AO = s ( t ) + vA t
Equation 18
v = v(t  + A? / 2)
Equation 19
Thus v can be calculated from the midpoint of the previous and the average acceleration from 
between t - At and t + At:
v(t  + At 12)  = v(t  — At  / 2) + a At
Equation 20
And given that a can be calculated from m"7F(j,0» a new position can be given by:
s(t  + At)  = ^(0 + v(t  -  At  12) + m~lF ( s , t ) A t
Equation 21
Using this method results in the reduction of errors due to truncation, because acceleration is 
calculated at a different point in time to the velocity (19).
Ensembles
Ensembles are sets of thermodynamic parameters that keep various quantities constant, which are 
used to govern which of these variables are to be kept constant when performing a molecular 
dynamics simulation. These ensembles are generally based around the thermodynamic expression 
PV = nRT (P = pressure, V = volume, n = number of atoms or particles, R = Gas constant, T =
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temperature). Common ensembles are NPT, NVT and NVE. N; the number of particles (n) in the 
system, is always kept the same as none are added to, or taken away during the progression of the 
simulation. Pressure (P), temperature (T), volume (V) and energy (E); depending on the ensemble 
are kept constant.
Depending on the simulation some of these quantities can vary even if they are kept constant, but 
effort is made to correct this. Such an example is the NPA (Nose-Poincare-Anderson) method, 
which uses weightings for temperature and pressure to control their variation (20).
Molecular Orbital Calculations
Electrons are a basic part of an atomic structure which “orbit” the nucleus of an atom, which is 
considered to be fixed as stated by the Bom-Oppenheimer approximation (21). A molecular 
orbital is “like an atomic orbital, but spreads throughout the molecule” (22), and is the result of 
performing a self consistent field (SCF) linear combination of atomic orbitals (LCAO) (21) in an 
attempt to solve the Schrodinger equation (Equation 22). This gives a wave function as a function 
of time and can be thought of as the probability of observing an electron at a particular position at 
a specific time, which is given as the square of the wave function (7). It is the square of the wave 
function that is plotted to give graphical representations of orbitals (21).
H T = E 'P
Equation 22: Time independent Schrodinger equation. H = operator, ¥  = wave function, E = energy of the
system
Self-Consistent Fields (SCF)
In simple terms, the SCF method uses the idea that an electron moves in an average field with 
respect to the nucleus of the atom and other electrons (21).
Such methods are solved iteratively to approach a result, due to the many-electron nature of 
atoms and molecules and their interaction with each other. To obtain the orbital of one electron, 
the orbital for another is needed, thus a guess is made and the calculation is performed to get a 
rough result for each electron with respect to the other electrons and through an iterative process 
the overall molecular orbitals are calculated. Each time the calculation is performed for each
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electron, improved versions of each orbital is obtained. Thus the interaction between electrons is 
taken into account as an average interaction (7, 19, 21, 22).
Linear Combination of Atomic Orbitals (LCAO)
In order to get a full picture of the molecular orbital for a molecule, SCF orbitals are combined in 
a linear manner (i.e. they are added together). However owing to the complexity of the 
calculations involved, these orbitals are simplified and called basis functions. A basis function 
can take any form as its description of the orbital; for example Gaussian function. A collection of 
basis functions comprise a basis set (7, 19, 21).
Basis sets
A basis set is a set of approximations of atomic orbitals used in the calculation of molecular 
orbitals. Basis sets are introduced to reduce the amount of computational power and time required 
to perform the calculation; however, the smaller the basis set the poorer the representation of the 
molecular orbital.
In this thesis a contracted basis set is used, this means that full sets of basis functions (primitive 
Gaussian type orbitals or PGTOs) are combined into a smaller set of functions (contracted 
Gaussian type orbitals or CGTOs). The foundation of a contracted basis set is that it becomes 
more difficult to calculate orbitals for the core electrons with little increase in accuracy. 
Considering the core electrons relatively small effect on binding as the important region is the 
outer valence electrons, it is inefficient to expend computational resources on describing the 
chemically uninteresting part of the wave function which is almost constant. Thus, the core 
electrons are described by a combination of basis functions. In order to clearly illustrate this, the 
3-21G basis set is discussed in brief.
The basis set 3-21G is a “split valence basis”; this is where core orbitals are a contraction of three 
PTGOs, inner valence orbitals are a contraction of two PTGOs and the outer valence orbitals are 
contracted to one PTGO (7).
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A model of HNF4a: combining the DNA Binding Domain with the Ligand Binding 
Domain 
Introduction
Hepatocyte nuclear factor 4a (HNF4a) is an orphan member of the nuclear receptor superfamily 
that exclusively dimerises with another monomer of its type (Group IV nuclear receptor) (1). It is 
known to regulate the expression of genes involved in liver differentiation as well as lipid and 
glucose metabolism.
To date no full length structure of the HNF4a homodimer has been determined, however there 
are crystal structures of both the lone DNA binding domain (DBD) (2) and ligand binding 
domain (LBD) (3) as homodimers.
The work presented in this chapter documents the construction of a model of HNF4a that 
comprises the DBD and LBD bound to DNA as a homodimer. This model is also used to identify 
how the monomers dimerise and any novel contacts between these that have not previously been 
seen through the examination of X-ray crystal structures. Also noted are any mutations associated 
with these contacts linked to maturity onset diabetes of the young (MODY).
Searching for templates
Owing to the high degree of homology and a similar modular (conserved functional domains) 
arrangement reported with in the nuclear receptor (NR) superfamily (4); similarity searches using 
BLAST (5, 6) result in mainly NR sequences being returned. Until recently there have been no 
crystal structures of more than small fragments of NRs (Ligand Binding Domains (LBD) and 
DNA Binding Domains (DBD) on their own) which may not be representative of full length 
structures. This is particularly the case for HNF4a(7). There are also parts of the HNF4a 
sequence that have either little or no similarity to any available sequence with an associated 
structure, such as the F-domain (7).
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Similarity to Nuclear Receptors 
Sequence Alignment
The full length HNF4a sequence was aligned with that of nuclear receptors of potential interest 
to this project. This includes the Progesterone Receptor (PR), Glucocorticoid Receptor (GR), 
Estrogen Receptor (ER), Retinoid X Receptor a  (RXRa) and Peroxisome Proliferator Activated 
Receptor y (PPARy). The difference between these sequences and that of HNF4a is expressed as 
% identity (amount of residues appearing in the same place in the sequence that are identical; 
expressed as a percentage) and %homology (the amount of hydrophilic and hydrophobic residues 
that match in the two sequences) are shown in Table 3: Nuclear receptor similarity to HNF4D 
Full Length
Table 3: Nuclear receptor similarity to HNF4a Full Length
Sequence code_________Name/ Description________ %ldentity %Homology
RXRA HUMAN Retinoid X Receptor 28.6 52
PPARG HUMAN Progesterone Proliferator activated 22.1 45.5
Receptor
ESR1_HUMAN Estrogen receptor 21.6 44.1
GCR HUMAN Glucocorticoid receptor 14.2 33.1
PRGR_HUMAN Progesterone receptor 14.3 29.9
According to the alignments performed here (Table 3), the best template for an homology model 
would be an experimentally determined X-ray crystal structure of RXRa. As shown in Figure 26 
there is a high degree of homology and identity with in both the DBD (DNA Binding Domain) 
and LBD (Ligand Binding Domain).
Inspection of the alignments (Figure 26) shows that the highest degree of similarity occurs with 
in the DBD and LBD of the NRs which is consistent with the literature (8).
Out of the alignments presented, PR is the only one that aligns with the F-domain repressive 
domain in HNF4a.
In order to further investigate the alignment of the majority of the C-terminus the 
HNF4a sequence was truncated to just the LBD to the end of the F-domain (134-464) (Table 4). 
This resulted in similar alignments but significantly lower figures for identity and homology.
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Table 4: HNF4a 134-464 alignment with NRs
Sequence code_________ Name/ Description________ %ldentity %Homology
RXRA HUMAN Retinoid X Receptor 17.7 34
ESR1_HUMAN Estrogen receptor 12.7 28.7
PPARG_HUMAN Progesterone Proliferator activated 
Receptor
11.6 27
GCR HUMAN Glucocorticoid receptor 8.1 22.1
PRGRJHUMAN Progesterone receptor 9.2 22
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Figure 26: HNF4a alignment with RXRa. Alignment performed using EMBOSS (9,10) (“I” Identical (the 
same amino acid), conserved (similar), Not conserved (not similar)). Red: A/B (AF-1) Domain. Blue: 
DNA Binding Domain. Pink: Ligand Binding Domain. Green: F-Domain.
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Figure 27: HNF4a alignment with PPARy. Alignment performed using EMBOSS (9, 10) (“I” Identical (the 
same amino acid), conserved (similar), Not conserved (not similar)). Red: A/B (AF-1) Domain. Blue: 
DNA Binding Domain. Pink: Ligand Binding Domain. Green: F-Domain.
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Figure 28: HNF4a alignment with ER. Alignment performed using EMBOSS (9, 10) (“I” Identical (the same 
amino acid), conserved (similar), Not conserved (not similar)). Red: A/B (AF-1) Domain. Blue: DNA 
Binding Domain. Pink: Ligand Binding Domain. Green: F-Domain.
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Figure 29: HNF4a alignment with GR. Alignment performed using EMBOSS {9, 10) (“I” Identical (the same 
amino acid), conserved (similar), Not conserved (not similar)). Red: A/B (AF-1) Domain. Blue: DNA 
Binding Domain. Pink: Ligand Binding Domain. Green: F-Domain.
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Figure 30: HNF4a alignment with PR. Alignment performed using EMBOSS (9, 10) (“I” Identical (the same 
amino acid), conserved (similar), Not conserved (not similar)). Red: A/B (AF-1) Domain. Blue: DNA 
Binding Domain. Pink: Ligand Binding Domain. Green: F-Domain.
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Similarity to Thioesterase Proteins
HNF4a has been reported to bind fatty acyl-CoA thioesters (7, 11) and have thioesterase 
functionality (12), according to these reports this is likely to be located near or in the F-domain of 
HNF4a. Thioesterase enzymes that have published X-ray crystal structures were investigated; in 
order to provide a potential template for a model of the F-domain of HNF4a.
A small selection of thioesterase proteins were aligned against the HNF4a sequence in order to 
find a common motif for thioesterase activity with in HNF4a. There are two overall types of 
thioesterase structure looked at here: a/p hydrolysis and Hotdog (Hotdog refers to the structural 
shape of the enzyme family). As with the NRs, both full length and 134-464 length sequences of 
HNF4a were aligned; however only thioesterases with 3D crystal structures were used (Table 5). 
Table 5: Thioesterase alignment with HNF4a
PDB code Sequence code hotdog /  
a/p
FU 134- 
end
%ldentity %Homology
2fuj Q8PBH4_XANCP hotdog FL 8.2 17.7
2v1o BACH_MOUSE hotdog FL 17.3 36.4
1bvq 4HBT_PSEUC hotdog FL 7.5 14
1q4u Q04416_9MICC hotdog FL 9.7 21
1ei9 PPT1 BOVIN ot/(3 FL 11.6 27.1
2px6 FAS_HUMAN a/p FL 5.5 11
1tht LUXDJVIBHA a/p FL 12.5 29.2
1v2g TESA_ECOLI a/p FL 12.1 25.7
1 pja PPT2_HUMAN a/p FL 11.2 22.4
2fuj Q8PBH4_XANCP hotdog 134-end 11.4 25
2v1o BACH MOUSE hotdog 134-end 15.6 39.3
1bvq 4HBT_PSEUC hotdog 134-end 7.9 15.7
1q4u Q04416_9MICC hotdog 134-end 6.9 22.2
1ei9 PPT1_BOVIN a/p 134-end 15 30.8
2px6 FAS_HUMAN a/p 134-end 3.5 7.4
1tht LUXD_VIBHA a/p 134-end 14.1 33.6
1v2g TESA_ECOLI a/p 134-end 12.4 24.4
1 pja PPT2_HUMAN a/p 134-end 14.5 28.7
The highest scoring thioesterase aligned with HNF4a was the “Crystal structure of N-terminal 
domain of acyl-CoA thioesterase 7” (PDB code: 2vlo) (13) for both the full and 134-464 length 
HNF4a sequence. However, the available structure is not long enough to cover the end of the 
available HNF4a structure and the F-domain of HNF4a (Figure 31) and is thus not a useful basis 
for a new structure. The RMS deviation of coordinates for this overlay is also 17.37A showing 
that the structures are too dissimilar. This is also the case for the most similar a/p hydrolysis type
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thioesterase (Figure 32), the RMS for the structural overlay is calculated as 19.68A. This is an 
even worse fit than the hotdog type.
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Figure 31: HNF4a alignment with acyl-CoA thioesterase 7 (PDB code: 2vlo). Alignment performed using 
EMBOSS (“I” Identical, conserved, Not conserved). Dark blue underline: thioesterase available 
structure. Red overline: HNF4a available structure. Red highlight: A/B Domain. Blue highlight: DNA 
Binding Domain. Pink highlight: Ligand Binding Domain. Green highlight: F-Domain.
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Figure 32 HNF4a alignment with Mysistoyl-ACP-Specific thioesterase (PDB code: ltht). Alignment 
performed using EMBOSS (“I” Identical, conserved, Not conserved). Dark blue underline: thioesterase 
available structure. Red overline: HNF4a available structure. Red highlight: A/B Domain. Blue highlight: 
DNA Binding Domain. Pink highlight: Ligand Binding Domain. Green highlight: F-Domain.
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Homology Modelling of the HNF4a DNA Binding Domain
Owing to the high degree of sequence homology between the HNF4a and RXRa DBDs, the 
RXRa crystal structure would be a good structure on which to base an homology model. RXRa 
is similar to HNF4a in that it binds to DNA as a DR1 as homodimers (14, 15) (direct repeat with 
separation of 1 nucleotide).
The crystal structure used as a basis was a homodimer of the RXRa DBD bound to its DR1 
response element. The HNF4a DBD sequence was aligned with the sequence of the RXRa 
crystal (PDB code: lby4 (14)), using MOE (16) and its default settings (Blosom62, Gap start: 7, 
Gap extend: 1). An alignment with 90% homology and 60% identity calculated for only the 
aligned section, 79 amino acids (Figure 33).
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Figure 33: MOE alignment of RXRa (aa: 131-209) and HNF4a (aa: 47-125)
The homology modelling tool with in MOE was then used to produce a database of 10 
preliminary models with slightly different loop and side chain rotamer candidates. All were 
minimised to an RMS gradient (The RMS gradient is a cut-off for the calculation, based on the 
gradient of the calculation and the number of unfixed atoms) of 1.0 kcal/molA; and a final 
model, chosen from the initial 10, was minimised to a gradient of 0.5 kcal/mol A.
The default settings were used with the AMBER99 (17-19) forcefield for the model refinement. 
This is a good fit to the crystal with an RMS of 0.55A (Figure 34); the closer this value is to 0A 
indicates less of a difference between the two structures.
A crystal structure of the HNF4a DBD was published once this work had been completed (15); 
the model produced here was compared to that crystal structure (Figure 35); as was the crystal 
structure of RXRa the model was based on (Figure 36) in order to validate the model produced, 
showing it is close to the experimental data (14, 15).
The first sequence chains in the crystal structures of the two DBDs were aligned using the same 
method as described above, and then superimposed; with a resulting RMS of 0.86A.
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Figure 34: Structural overlay of the HNF4a (Red ribbon) final model on to the RXRa crystal (PDB code: 
lby4) (Green). RMS: 0.55A
Figure 35: HNF4a model based on RXRa (Red) overlaid on to the HNF4a crystal structure (Grey) (PDB code 
3cbb (75)). RMS: 0.97 A
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Figure 36: HNF4a DBD crystal structure (PDB code 3cbb) (Grey) superimposed on to the RXRa DBD crystal 
structure (PDB code lby4) (Red) RMS: 0.86A
Ramachandran plots (20, 21) were used to validate the model. The plot produced for the model 
based on the RXRa DBD showed that no outliers were present. This is also the case for the 
crystal structure of the HNF4a DBD (Figure 37). The alignment (Figure 33) RMS deviation and 
comparison with other known structures of DBDs, show that this crystal (PDB code lby4) would 
be a good basis for a larger and more complete model of the HNF4a structure.
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Figure 37: Ramachandran plot for HNF4a model based on RXRa all residues are with in the allowed regions 
(orange contours) and with the majority in the preferred regions (green contours) (Image produced using 
MOE (16))
Homology Modelling of the HNF4a Ligand Binding Domain
All the available crystal structures (Human: lpzl (22). Rat: lm7w (3)) of the HNF4a LBD have a 
fatty acid bound to the active site. The crystallized rat form of HNF4a shows two distinct 
structures, one with a closed binding site where helix 12 has curled round and covered the 
binding site, assumed to be the active form and the other structure where helices 10 -  12 are 
continuous leaving the binding pocket open (Figure 39). In the RXRa unliganded structure and 
other nuclear receptors, helix 12 is still extended, however helix 11 is bent into the empty binding 
pocket (22) (Figure 38).
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B
Figure 38: A: RXRa with out ligand (PDB code: 1LBD (23)) B: RARy with ligand bound (PDB code: 21bd 
(24)) (Images produced using Accelrys Discovery Studio Visualizer) (25)
B
Figure 39: A: Rat HNF4a homodimer with ligands bound to both “active” (left) and “inactive” (right) (PDB 
code: lm7w) (22). B: Human HNF4a monomer with ligand bound (PDB code: lpzl) (3)
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Homology Modelling of the inactive HNF4a LBD
Owing to the lack of an apo (unliganded) crystal structure for HNF4a, it is not known if the apo 
form will have the same conformation with in helices 10-12 as RXRa and other NRs. To 
investigate this, a molecular dynamics calculation was performed on the form of HNF4a without 
the ligand bound to the active site (apo). The inactive monomer (with extended helix 12) was 
selected from the crystal structure of the rat HNF4a (PDB code: lm7w chain 2). Owing to 
missing residues with in the crystal structure, it was necessary to build a model of the human 
form based on the selected chain. The rat crystal structure and human sequences were aligned and 
a model built using MOEs homology modelling tool methods as described for construction of the 
DBD model. For the parts of the sequence aligned (Figure 40), the rat crystal structure was 93% 
identical to the human sequence and 94% homologous. The rat sequence has a 10 amino acid gap 
that does not align as it was not crystallized with the rest of the structure.
R at
jumar L P S  I N A L L Q A E V L S R Q  I T S P V S G  I N G D  I R A K K  I A S  I A D V C E S M K E Q L L V L V E W A K Y  I P A F C
L P S I N A L  L Q A E V  L S Q Q I T R A K R I  A S  I T D V C E S M K E Q L L V L V E W A K Y I P A F C
R at
pymagE L P  L D D Q V A L  L R A H A G E H L  L L G A T K R S M V F K D V L  L L G N D Y  I V P R H C P E L A E M S R V S  I R I L D  
E L  L L D D Q V A L  L R A H A G E H L L  L G A T K R S M V F K D V  L L L G N D Y I V P R H C P E L A E M S R V S I R I L D
R at
H y D H ) E L V L P F Q E L Q  I D D N E Y A Y L K A  I I F F D P D A K G L S D P G K  I K R L R S Q V Q V S L E D Y  I N D R Q Y D S R  
E L V L P F Q E L Q I D D N E Y A C L K A I  I F F D P D A K G L S D P G K I K R L R S Q V Q V S L E D Y I N D R Q Y D S R
R at
( H u m a n j G R F G E L L L L L P T L Q S  I TWQM I E Q I Q F  I K L F G M A K  I D N L L Q E M L L G  
G R F G E L L L L L P T L Q S I T W Q M I E Q I Q F I K L F G M A K I D N L L Q E M L L G
Figure 40: Corresponding human LBD sequence aligned with the rat crystal structure chain 2 (PDB code: 
lm7w)
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Figure 41: Ramachandran plot for human HNF4a model based on rat HNF4a crystal structure. Residues 
with in preferred regions: green, residues with in allowed regions: yellow, outliers: red crosses.
Inspection of the Ramachandran plots for the model and the original structure shows that the 
model contains fewer outliers (Figure 41) than the original structure (Figure 42). This is an ideal 
starting point for a molecular dynamics simulation, as there are few geometrical anomalies 
associated with the structure.
The molecular dynamics simulation was instructed to record a step every 0.5ps (picoseconds) at a 
constant temperature of 300K for Ins (nanosecond), with a time step of 0.00lps. The algorithm 
employed was the NPA (Nose-Poincare-Anderson (26)) with an NVT ensemble: this required a 
temperature weighting of 0.05. The forcefield used in this simulation was AMBER99 with a 
dielectric of 4 (no units) for the protein and 80 for the exterior (solvent). This resulted in a stable 
simulation after initial equilibration of the structure with in the conditions of the calculation. The 
simulation was considered to have equilibrated after the first lOOps. Drift in the plot of the value 
of output from the calculation (the value of the Hamiltonian H) indicates too large a time step. 
Using the time step given above, a gradient (representative of the drift in the simulation) of - 
0.00017 (H plotted against time) resulted, indicating negligible drift in the simulation (Figure 43).
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Figure 42: Ramachandran plot for the rat HNF4a crystal structure Residues with in preferred regions: green, 
residues with in allowed regions: yellow, outliers: red crosses.
Time vs MD output
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Figure 43: Time (t) vs. the Hamiltonian, Le. the value for the full extended system (H) for the MD simulation 
of the Human unliganded inactive model, after equilibration.
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The calculated RMS of an overlay between the starting point and the final model from the MD 
simulation (Figure 44) is 7.26A. This difference is to be expected as the system has absorbed 
energy from the rise in temperature to that at which the calculation is carried out, causing a lot of 
general movement. The structure has retained the general nuclear receptor structure, and the 
binding site has closed up with helix 11 moving towards the pocket as with other NRs. Helix 12 
has bent over the rest of the structure and remains there throughout most of the simulation.
Figure 44: A: Starting point for MD simulation (663 kcal/mol). B: final model output from the MD simulation 
(2462 kcal/mol).
Modelling of the HNF4a activated Ligand Binding Domain
For the combined DBD-LBD; a model of the LBD with the ligand in place and the structure in an 
activated conformation, was constructed. The first model to be built was based on the crystal 
structure of the human HNF4a LBD (PDB code: lpzl)
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Human: Activated Model
The sequence for the full LBD was aligned manually for a good structural fit with the sequence to 
that of the human HNF4a crystal structure. MOE’s homology modelling tool was employed with 
default settings to build the model. Once again the AMBER99 forcefield was used. The final 
model output by the homology modelling tool was used and the coordinates from the crystal 
structure were overlaid in order to insert the ligand into the binding site in the correct orientation. 
The ligand, surrounding atoms (with in 4.5A) and associated residues were minimised to a 
gradient of 0.05 kcal/mol A using AMBER99 to eliminate any unfavourable geometries. The 
whole model was then minimised to a gradient of 0.05 kcal/mol A.
Figure 45: Overlay of the model onto the crystal structure, Red: Crystal structure of HNF4a LBD (PDB code: 
lpzl) Pink: Homology model of HNF4a LBD. RMS: 1.1 A. The ligands are shown in space fill representation.
The resulting model was overlaid on to the coordinates of the crystal structure and an RMS of 
1.1 A was calculated (Figure 45). This is a good fit and suggests that the crystal structure of 
human HNF4a (PBD code: lpzl) is a suitable template for part of a model of the more complete 
DBD-LBD. Ramachandran plots were also generated, and show that the model has no outlying 
geometries, whereas that of the original crystal structure shows three outliers (Figure 46, Figure 
47).
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Figure 46: Ramachandran plot for the human HNF4a crystal structure (PDB code lpzl). Residues with in 
preferred regions: green, residues with in allowed regions: yellow, outliers: red crosses.
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Figure 47: Ramachandran plot for the human HNF4a model. Residues with in preferred regions: green, 
residues with in allowed regions: yellow, outliers: red crosses.
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Rat: Activated Model
A second model was built based on the activated conformation of the rat crystal structure (PDB 
code: lm7w). This was constructed using the same method as that based on the human crystal 
structure.
The basic structure was prepared by deleting all unnecessary chains and aligning the human 
sequence with that of the remaining chain manually. The ligand was added into the model’s 
binding pocket by the superimposition of the human crystal structure on to the coordinates of the 
new model (RMS: 1.1 A) and deleting all non-essential chains leaving the ligand in the pocket. 
The ligand and atoms with in 4.5A were selected; this selection was extended to the rest of the 
partially selected residues. These were then minimised to a gradient of 0.05 kcal/mol A. The 
whole structure was then minimised to the same gradient.
Figure 48: Human HNF4a LBD model based on rat HNF4a LBD crystal structure (Red ribbon) overlaid onto 
Human HNF4a LBD crystal structure (Blue ribbon) (RMS: 1.5A)
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Figure 49: Ramachandran plot for Human HNF4a LBD model based on rat HNF4a LBD crystal structure
A good quality model was produced with a high degree of similarity with the human HNF4a 
LBD crystal structure (RMS: 1.5A) (Figure 48) and few outlying residues according to 
Ramachandran plots (Figure 49). Although this is not as good as the model based on the human 
HNF4a LBD crystal structure, the rat crystal has the advantage of being crystallised as a 
homodimer not a monomer. This is advantageous as it provides a set of coordinates that define 
how the two monomers in the homodimer interact. For this reason, the rat crystal structure of the 
HNF4a LBD was used as a basis for a combined DBD -  LBD model.
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Homology modelling of the combined DBD and LBD of the human HNF4a 
homodimer bound to DNA
The templates used for the modelling of the combined DBD -  LBD HNF4a homodimer are the 
crystal structure of the human RXRa DBD homodimer bound to its response element (PDB code: 
lby4) and the activated conformation from the crystal structure of the rat form of the HNF4a 
LBD (PDB code: lm7w).
Building a model of the combined HNF4a DBD-LBD
The crystal structure of the RXRa DBD was loaded into MOE with the crystal structure of the rat 
HNF4a LDB homodimer crystal structure with unwanted chains removed. These include solvent 
molecules that were crystallised with the rest of the structure (considered as chains by MOE, with 
multiple solvent molecules per chain) and a second homodimer in the crystal structure to be used 
as a basis for the model. The homodimer chains were then moved manually into a position where 
the ends of the chains that should join would be with in easy reach of each other: these ends are 
shown in space filled representation (Figure 50).
The full length HNF4a sequence was aligned with that of the first RXRa DBD chain (Yellow 
chain: Figure 50) and the first chain of the HNF4a LBD (Green chain: Figure 50). Figure 51 
shows the alignment for these chains and only the selected residues were used as templates to 
build the model of the monomer: this selection is as shown by the highlighting in Figure 51. The 
same alignment and homology modelling methods were used as previously described for the 
building of the separate domains (DBD and LBD).
-91 -
Chapter 3 - A model of HNF4a:
Combining the DNA Binding Domain with the Ligand Binding Domain
Figure 50: Left complex: RXRa DBD crystal structure (lby4), Right complex: Rat HNF4a LBD homodimer. 
Orange space fill: ends to be joined for monomer 1 (Figure 52). Red space fill: ends to be joined for monomer 
2 (Figure 54).
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Figure 51: First monomer (Figure 52) alignment. Yellow highlight: DBD. Green highlight: LBD.
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Figure 52: Stereo view of the homology model of the first monomer constructed.
For the second monomer constructed (Figure 54), it was decided to use the activated form of 
HNF4a for a full combined model of the homodimer. This was accomplished by superimposing 
the coordinates of the activated conformation onto the coordinates of the inactive form so as to 
maintain the dimerization interface between the two monomers (RMS: 6.65A). The red space 
filled residues denote where the missing hinge sequence will fit into the model (Figure 53). This 
set of new coordinates was then used to build the model of the second monomer in the same way 
as the first monomer model (Figure 54).
The Ramachandran plots for the two monomers (Figure 55 & Figure 56) show that there are a 
large number of outlying residues. The two monomers were combined on the DNA response 
element from the RXRa DBD crystal structure. This is accomplished by overlaying the 
appropriate monomers onto the appropriate crystal chains from the RXRa DBD crystal structure. 
The solvent and protein chains from the crystal were then removed leaving only the DNA strands 
and the zinc ions in place. The ligands were inserted into the binding sites by the same 
methodology used in the building of the previous LBD models.
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Figure 53: Superimposition of the active conformation of HNF4a (Yellow ribbon) on to the coordinates of the 
inactive form of HNF4a (Purple ribbon) (RMS: 6.65A)
Figure 54: Stereo view of the homology model of the second monomer constructed.
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Figure 55: Ramachandran plot for the first monomer on its own.
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Figure 56: Ramachandran plot for the second monomer on its own.
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Once all the essential components were added into the model, it was refined. The DNA atoms 
were tethered to their coordinates with a weight of 500 in order to hold them in place during the 
refinement stage of the model building. Any atom clashes identified by MOE’s protein geometry 
analysis tool were dealt with by selecting the concerned atoms, the residues they are part of and 
any residues that fall with in 4.5A of the affected residues and minimised to a gradient of 0.05 
kcal/molA. This procedure was also followed for any outlying residues identified by 
Ramachandran plots.
The zinc atoms with in the DNA binding domain were given a charge of 2+ and moved manually 
into a position where they can coordinate with the relevant cysteine residues. MOE’s Protonate 
3D tool was then used to protonate the system at physiological pH (pH 7.4) at 300K with default 
settings for the tool. The dielectric for the system was set at 4.0 with the solvent set to the default 
of 80. The zinc atoms were selected with the residues with in 4.5A, and the Protonate 3D tool 
used again with the same settings on these selected atoms. This resulted in the sulphur atoms on 
the cysteine residues being deprotonated and given a charge of -1.05.
These atoms were then minimised until the zinc atoms had a tetrahedral coordination with the 
sulphur on the cysteines (Figure 57). The ligands were also protonated in the same manner. The 
system was then minimised to a gradient of at least 0.1 kcal/mol A to prepare it for a molecular 
dynamics simulation. The locations of the ligands and zinc ions with in the model are shown in 
Figure 58.
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Figure 57: Stereo view of zinc 2+ coordinated with cysteines with in the DBD of the combined DBD -  LBD 
HNF4a model
Ligands
Zinc atoms
Figure 58: Stereo view of the final model ready for a Molecular Dynamics simulation. Zinc atoms and ligands 
shown in space fill
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Molecular dynamics of the combined DBD-LBD model
In order to validate and investigate the stability of the combined model, a molecular dynamics 
simulation was performed. The starting point for the simulation is shown in Figure 58. The 
simulation was set to run for lOOOps (Ins) at a simulated temperature of 300K. A snapshot of the 
calculation was taken every 0.5ps with a time step calculated every 0.00lps (lfs 
(femptoseconds)). The NPA algorithm was used to run the simulation with the NVT ensemble: 
this required a temperature weighting (QT) of 0.05 giving a fairly rigid temperature control; to 
produce a stable output. Aside from these parameters, the default settings were employed: only 
light bonds are constrained, these include bonds to hydrogens and lone pairs, with a Tol value of 
le-12, specifying that the constraint equations be solved to a more accurate degree than if set to a 
higher value. Water was assumed to be rigid.
Time vs MD output
45
40
-0.0004X + 37.566
o
E
to
X
0 100 200 400300 500 600 700 1000800 900
Time: t  (ps)
Figure 59: Time (t) vs. the Hamiltonian i.e. the value for the full extended system (H) for the MD simulation of 
the Human combined model, including equilibration (first lOOps)
Figure 59 shows that a stable simulation was achieved after initial equilibration; the trendline in 
red shows the stable region that is used for analysis of contacts between the monomers.
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Figure 60 depicts the model after Ins of molecular dynamic simulation. The structure shown has 
retained the general overall structure of the starting point and kept ligands and zinc ions in the 
same positions, indicating a stable simulation.
The Ramachandran plots shown in Figure 61 and Figure 62; show a “before and after” view of 
how the molecular dynamics simulation has affected the overall structure. Figure 62 shows that 
there are in fact fewer outliers after the simulation indicating a more stable model than the 
starting point. Even though Figure 60 shows that the model seems to have a more disordered 
structure than the starting point (Figure 58), it has to be kept in mind that this is snap-shot of the 
overall simulation; where the temperature has been raised to 300K and thus a greater amount of 
energy is present with in the system; thus movement (and therefore geometrical changes) in the 
structure are to be expected.
Figure 60: Stereo view of the combined model after lOOOps of MD simulation.
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Figure 61: Ramachandran plot of the combined homodimer model, before the Molecular Dynamics 
simulation.
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Figure 62: Ramachandran plot of the combined homodimer model, after the Molecular Dynamics simulation.
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The simulation was considered to be equilibrated after lOOps of calculation; samples were taken 
starting at the 501st step in the calculation and every 250 steps after: this is equivalent to starting 
at 250ps and 125ps intervals. This gave seven models with slightly different conformations. 
MOE’s contact analysis tool was used to identify sidechain to sidechain interactions between the 
two monomers. For each of the sample models the recorded contacts were split into one of four 
categories:
• Unreported contacts: contacts between residues that have not been reported in the 
literature (Table 6 , Table 7 and Table 8).
• Reported and unreported: reported residues reported to contact their reported residue, 
contacting a residue that has not been reported to contact any residues (Table 9 and Table 
10).
• Reported contacts: contacts between residues that have been reported in the literature 
(Table 11 Table 12 Table 13).
• Reported to other reported: residues that have been reported to contact a particular residue 
contacting another residue has been reported to contact another particular residue (Table 
14).
These contacts are subdivided by their interaction type: hydrogen bonding, hydrophobic and 
ionic. Interactions are ranked according to their occurrence out of the seven samples.
If an interaction occurs multiple times in the group of samples it is more likely to be a common 
interaction. Table 6, Table 7 and Table 8 show a number of previously unreported interactions 
derived from the molecular dynamics simulation, mutations linked to Diabetes MODY or 
MODY1 (27) are marked in bold.
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Table 6: Unreported hydrogen bonding contacts ranked according to occurrence (Bold: mutation)
Monomer 1 Monomer 2 Occurrence
LYS99 ASN123 M l
ASN101 GLN122 2/7
GLU344 GLN347 2/7
GLU344 GLN362 2/7
ARG244 ASP295 3/7
ASP289 THR334 3/7
ASP289 SER337 All
GLN92 ARG127 4/7
LYS291 SER337 4/7
ARG254 GLU363 5/7
SER337 ASP289 5/7
GLU262 LYS291 6/7
ASP98 LYS118 6/7
SER90 ARG131 6/7
ASP320 ARG132 7/7
LYS291 GLU344 7/7
Table 7: Unreported hydrophobic contacts ranked according to occurrence
Monomer 1 Monomer 2 Occurrence
ILE343 ILE343 2/7
PHE348 LEU351 3/7
ILE343 PHE348 4/7
PHE348 PHE348 5/7
Table 8: Unreported ionic contacts ranked according to occurrence (Bold: mutation)
Monomer 1 Monomer 2 Occurrence
ASP295 ARG244 1/7
ASP320 ARG131 1/7
LYS231 ASP295 1/7
ARG254 GLY367 2/7
ARG244 ASP295 4/7
ARG254 GLU363 5/7
ASP98 LYS118 6/7
ASP320 ARG132 7/7
GLU262 LYS291 7/7
LYS291 GLU344 7/7
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Table 9: Reported and unreported hydrogen bonding contacts (Bold: mutation)
Monomer 1 Monomer 2 Occurrence
GLN102 ARG127 1/7
SER304 GLU327 1/7
ASP289 ARG258 2/7
GLU327 SER304 2/7
TRP340 SER337 2/7
ARG258 ASP289 An
ARG322 GLU136 AH
ARG303 THR334 5/7
LYS99 GLU124 5/7
ARG301 GLU269 6/7
GLU269 ARG301 6/7
ASN315 GLU311 6/7
Table 10: Reported and unreported ionic contacts (Bold: mutation)
Monomer 1 Monomer 2 Occurrence
ARG301 GLU327 1/7
ARG258 GLY367 2/7
ARG303 GLU262 2/7
ASP289 ARG258 5/7
ARG258 ASP289 6/7
ARG322 GLU136 6/7
LYS99 GLU124 6/7
ARG301 GLU269 7/7
GLU269 ARG301 in
Table 11: Reported hydrogen bonding contacts (Bold: mutation)
Monomer 1 Monomer 2 Occurrence
GLN102 GLU124* M l
GLU327 GLN307 3/7
ARG322 ASP312 6/7
GLU327 ARG303 6/7
ARG303 GLU327 7/7
GLU269 LYS300 H I
LYS300 GLU269 m
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Table 12: Reported hydrophobic contacts (Bold: mutation)
Monomer 1 Monomer 2 Occurrence
ILE343 ILE343 2/7
ILE283 LEU330 5/7
LEU329 LEU329 6/7
LEU330 LEU332 6/7
LEU332 LEU330 6/7
TRP340 TRP340 6/7
LEU330 ILE283 7/7
PHE325 PHE325 7/7
Table 13: Reported ionic contacts (Bold: mutation)
Monomer 1 Monomer 2 Occurrence
ASP312 ARG322 1/7
LYS300 GLU327 1/7
GLU327 ARG303 6/7
ARG303 GLU327 7/7
ARG322 ASP312 7/7
GLU269 LYS300 7/7
LYS300 GLU269 717
Table 14: Reported and other Reported contacts (Bold: mutation)
Type Monomer 1 Monomer 2 Occurrence
HB ARG322 GLU311 217
HB GLU311 ARG322 3/7
HYD PHE325 LEU329 1/7
HYD LEU330 LEU329 3/7
HYD LEU329 LEU330 7/7
ION ARG322 GLU311 6/7
ION GLU311 ARG322 6/7
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Table 15: Reported dimerization interactions (Dhe-Paganon. et al. 2002 & Lu. et al. 2008)
Residue 1 Residue 2
Asp126 Arg88
Gln307 Glu327
Glu311 Gly323
Gln336 Gln336
Phe325 Phe325
Leu329 Ieu329
Leu330 Ile283
Leu332 Leu330
Pro333 Pro333
Trp340 Trp340
Glu269 Lys300
Arg303 Glu327
Arg322 Asp312
Discussion
The most interesting contacts reported here are those that are previously unseen and that occur in 
all the samples taken from the molecular dynamics simulation. There are three such contacts 
shown here (Table 8): Asp320: Argl32, Glu262: Lys291 and Lys291: Glu344.
The interaction between Asp320 and Argl32 is of particular interest for this model, as it involves 
Argl32, which is located with in the hinge region that is not crystallised in any of the crystal 
structures. Asp320 is located in the loop between helices 9 & 10. It is possible that this 
interaction in this model serves as a structural hold, rather than a functional purpose. It may well 
serve to hold helix 9 in position in order for an interaction between helix 9 and the DBD of the 
same monomer (Figure 63).
The residue Lys291, located in the loop between helices 8 & 9, is involved in different 
interactions in both monomers, one with Glu262, the other with Glu344. Lys291 may contact 
both these residues regularly to hold the two monomers together enhancing the dimerization of 
the monomers and contributing to enhanced transcription. Inspection of these residues in the rat 
x-ray crystal structure shows that Glu262 is the nearer of the two residues to Lys291 suggesting 
that it is the more likely contact (Figure 64). However, it is not inconceivable that contact with 
Glu344 will take place due to the dynamic nature of the system. The proximity of the residues 
Lys291 and Glu344 may only be a feature of the truncated form of the sequence. A repressor 
domain present towards the C-terminus of the F-domain (aa: 430-441); aligns with a similar 
region with in PR (progesterone receptor) (28) that would bind between monomers with the PR 
structure (29). This inhibition is demonstrated with a structural overlay of the PR LBD structure
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(PDB code: la28) on to the coordinates of the rat HNF4a LBD (Figure 65). If this is also the case 
with the HNF4a homodimer structure, then it would show that the interaction Lys291:Glu344 
helps enhance transcription. However, this is inhibited by this repressive domain bound between 
the monomers at the point at which these residues would make contact with each other. This 
would explain how the reported repressor region reduces the transcriptional activity of HNF4a.
Figure 63: Stereo view of the interaction between Asp320 and Argl32.
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Figure 64: Stereo view of the distance between Lys291&Glu344 and Lys291&Glu262 with in the crystal 
structure of the rat HNF4a LBD homodimer (PDB code: lm7w).
Figure 65: Stereo view of the overlay of the PR crystal structure (Pink ribbon) onto the HNF4a rat 
homodimer (PDB code: lm7w, Green & Red ribbons) Yellow Ribbon: Repressor region on the PR structure. 
Overlay RMS deviation: 4.4A.
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An example of mutations associated with HNF4a is Argl27 which mutates to Trp leading to 
diabetes MODY1 (30). According to the simulation, Argl27 interacts with Gln92 in more than 
half of the samples investigated. There are also cases of a residue not reported to interact with 
residues that interact with other residues in a known way, these interact to form part a larger 
network. Glu269 is reported to interact with Lys300 (3), and is shown to interact with Arg301 in 
this simulation. This interaction is likely to strengthen the hold between the two monomers, 
resulting in a stronger homodimer than that observed in the x-ray crystal structure. Inspection of 
the published x-ray crystal structure, focusing on these residues; shows that the Glu269:Lys300 
interaction occurs on only one side of the homodimer (Figure 66). In the model presented here it 
is shown that these interactions occur on both sides of the homodimer (Figure 67). This is not to 
say that the interaction does not occur on both sides; merely that the single view given by the 
crystal structure (a low energy conformation “snapshot” of a dynamic system) can be enhanced 
by observation of the system in motion.
Figure 66: Stereo view of the interaction between Glu269 and Lys300 in the x-ray crystal structure of the 
HNF4a homodimer.
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Figure 67: Stereo view of the interaction between Lys300, Arg301 and glu269 in the model of the HNF4a 
homodimer.
Arg301 is reported to mutate to Gln301, leading to diabetes MODY (31). This mutation may well 
have a destabilising effect on the interaction between Glu269 and Lys300. This destabilisation 
could result in a weakening of the hold between the monomers, potentially resulting in a 
reduction of function of the complex.
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Construction of an in silico  model of HNF4a based on the PPARy-RXRa 
heterodimer. 
Introduction
At the time that the work on the combined DBD (DNA Binding Domain) and LBD (Ligand 
Binding Domain) was being performed, as described in the previous chapter; the crystal 
structure of the combined DBD-LBD of the PPARy (Peroxisome Proliferator-activated 
receptor gamma)-KXRa (Retinoid X Receptor alpha) heterodimer was solved (1). Owing to 
the similarity of Nuclear Receptor (NR) sequences to the HNF4a sequence; the new PPARy- 
RXRa crystal structure could be an ideal template for a model of the ligand bound HNF4a 
homodimer. In this chapter a model of the ligand bound HNF4a combined DBD-LBD 
homodimer bound to DNA was constructed. This model reveals novel interactions between 
the monomers of the homodimer which may have implications for how transcription takes 
place and any mutations that lead to maturity onset diabetes of the young (MODY).
Similarity between HNF4aand PPARyand RXRa
In this section; the similarities between the sequence of HNF4a and those of the PPARy -  
RXRa heterodimer and a comparison of some of the available x-ray crystal structures, are 
examined.
HNF4a similarity with PPARy
The full length amino acid sequence for HNF4a was aligned with the full length isoform of 
PPARy (residues 1-505) that appears in the x-ray crystal structure of the PPARy-RXRa 
heterodimer (PDB code: 3dzy) (7), with EMBOSS (2-4), using the substitution matrix 
Blosum50 and the default settings (Gap start: 10, Gap extend: 0.5) (Figure 68). This gave an 
alignment where the % Identity (number of residues appearing in the same place in the 
sequence that are identical expressed as a percentage) is 21% and a % homology (the number 
of hydrophilic and hydrophobic residues that match in the two sequences) of 43%. This 
indicates a degree of similarity between the sequences.
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Figure 68: Alignment of full length PPARy and HNF4a by EMBOSS (4) (“I” Identical, conserved,
Not conserved). Red line: HNF4a crystal structures (DBD and LBD). Blue underline: Crystal structure of 
PPARy from the heterodimer as published by Chandra, et al. 2008. Red highlight: A/B domain. Blue 
highlight: DBD. Pink highlight: LBD domain as per crystal structures (HNF4a: PDB code lpzl (5), 
PPARy: PDB code 2ath (6)). Green highlight: F-domain.
In order to assess the structural similarity between HNF4a and the PPARy chain with in the 
PPARy-RXRa heterodimer crystal structure, the human H NF4a crystal structure coordinates
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of the Ligand Binding Domain (PDB code: lpzl (5)) were superimposed over those for 
PPARy (Figure 70). This was achieved by first aligning the sequences using the alignment 
tool with in MOE (7). Blosum62 was used to perform the alignment with the default settings 
(Gap Start: 7 and Gap Extend: 1). This resulted in the alignment presented in Figure 69.
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Figure 69: Alignment of the sequences associated with the human HNF4a LBD crystal structure (PDB 
code lpzl) and the PPARy monomer from the PPARy-RXRa heterodimer (PDB code 3dzy).
Once the alignment of the sequences was complete, the HNF4a structure was superimposed 
on to the coordinates of the PPARy structure; the RMSD for this overlay was 6.9A.
The DNA Binding Domain (DBD) was then treated in the same manner; the structure that 
was overlaid on to the coordinates of the heterodimer were those of the crystallised HNF4a 
DBD (PDB code: 3cbb) (8). For this domain (the aligned amino acids Figure 71) the value 
for % identity is 44% and a % homology of 83%, these values suggest a particularly high 
degree of similarity between the two sequences. The superimposition of the HNF4a crystal 
structure on to the coordinates of the heterodimer for PPARy only (Figure 72) resulted in an 
RMSD of 3.6A confirming the sequence similarity and indicating a very close structural 
similarity between the two structures.
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Figure 70: Stereo view of the overlay of the human HNF4a LBD crystal structure (PDB code lpzl) on to 
the PPARy monomer coordinates from the PPARy-RXRa heterodimer (PDB code 3dzy). Orange ribbon: 
PPARy monomer. Pink ribbon: RXRa monomer. Light blue & dark purple ribbons: DNA. Yellow 
ribbon: HNF4a LBD crystal structure. (RMSD: 6.9A)
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Figure 71: Alignment of the HNF4a DBD crystal structure (PDB code 3cbb) and the PPARy sequence 
from the PPARy-RXRa heterodimer crystal structure (PDB code 3dzy)
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Figure 72: Stereo view of the superimposition of the HNF4a DBD crystal structure (PDB code 3cbb) 
(Blue ribbon) on to the coordinates of the DBD of the PPARy monomer (Green ribbon) with in the 
PPARy-RXRa heterodimer. RMSD: 3.6A
HNF4a similarity with RXRa
In the previous chapter an alignment of the full length sequences of HNF4a and RX Ra was 
presented (Chapter 3: Figure 26), this alignment resulted in higher values of % identity and % 
homology (28% and 52% respectively) than reported here for between full length sequences 
of PPARy and HNF4a, suggesting a greater degree of similarity between the HNF4a and 
RX Ra structures. For the case of similarity between the HNF4a LBD structure (PDB code 
lpzl) and the RX Ra monomer from the PPARy -  RXRa crystal structure (PDB code 3dzy), 
the human HNF4a LBD crystal structure (PDB code lpzl) was superimposed upon the 
coordinates of the RX Ra monomer from the PPARy -  RX Ra heterodimer (PDB code 3dzy). 
The sequence alignment as presented in Figure 73 provides a superimposition with an RMSD 
of 1.76A indicating a high degree of structural similarity (Figure 74); higher than between the 
PPARy monomer and HNF4a.
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Figure 73: Alignment of the Human HNF4a LBD crystal structure sequence (PDB code lpzl) with that of 
the RXRa sequence from the PPARy-RXRa heterodimer (PDB code 3dzy) in preparation for structural 
superimposition. Based on the EMBOSS alignment presented in Chapter 3: Figure 26.
Figure 74: Superimposition of the Human HNF4a LBD crystal structure (PDB code lpzl) (Blue ribbon) 
on to that of the RXRa from the PPARy-RXRa heterodimer (PDB code 3dzy) (Red ribbon) RMSD: 
1.76A
The DNA Binding Domain for the RXRa monomer was also compared to that for HNF4a; 
this was achieved by aligning and superimposing the crystal structure of the HNF4a DBD
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(PDB code: 3cbb (5)) on to the coordinates of the RXRa monomer in the PPARy-RXRa 
heterodimer. Figure 75 & Figure 76 depict the alignment and the superimposition 
respectively.
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Figure 75: Alignment of the HNF4a DBD sequence from the crystal structure (PDB code 3cbb) with the 
sequence for the RXRa monomer in the PPARy-RXRa heterodimer (PDB code 3dzy)
on to
As reported in Chapter 3, the % homology and identity (90% and 60% respectively) for this 
domain are high, signifying a very similar sequence. The overlay of the two structures shows 
a very close structural similarity with an RMSD of 0.6A.
. P
Figure 76: Stereo view of the superimposition of the HNF4a DBD (PDB code 3cbb: Grey ribbon) 
the RXRa monomer in the PPARy-RXRa heterodimer (PDB code 3dzy: Red ribbon) RMSD: 0. 6A
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Building models of individual monomers for an HNF4a homodimer bound to 
DNA
In order to construct a model of the HNF4a LBD-DBD homodimer, the PPARy-RXRa 
heterodimer was used as a template to organise the positions in space of the domains of the 
HNF4a monomers, with respect to each other. The available crystal structures of 
HNF4a(DBD: 3cbb (8) & LBD: lm7w (9)) are superimposed onto the PPARy-RXRa 
heterodimer coordinates and it was these which formed the template for the homology model. 
This ensures that the model will be as close as is possible to the experimental data (available 
crystal structures); it will also preserve the dimerization interface between the two HNF4a 
monomers at both the DBD and the LBD. Each of the two monomers for the overall model 
are built on a monomer by monomer basis, these are then combined later for a complete 
model.
The PPARy-RXRa heterodimer structure (3dzy) was loaded into MOE, with the crystal 
structure of the HNF4a DBD (3cbb). 3cbb was overlaid on to the DBD of the heterodimer, in 
this case the best overall fit results from superimposing 3cbb on to the RXRa monomer 
DBD, with an RMSD of 0.6A. Figure 77 shows a comparison of a superimposition of 3cbb 
on to the RXRa monomer and 3cbb on to the PPARy monomer. This comparison clearly 
shows that the superimposition of 3cbb on to the RXRa DBD results in a better fit than 3cbb 
on to the PPARy DBD coordinates.
The crystal structure of the rat HNF4a LBD is superimposed on to the PPARy-RXRa 
heterodimer with a model of the human HNF4a LBD. The model of the human HNF4a is 
based on the crystal structure of the human HNF4a LBD and is constructed as described in 
Chapter 3. A model of the human HNF4a LBD was used due to the crystal structure 
containing a region (amino acids 158-163) that was not crystallized with the rest of the 
structure; this region is present in the model.
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Figure 77: Left: Superimposition of 3cbb (HNF4a DBD crystal structure) on to the DBD of the RXRa 
side of the heterodimer (3cbb: dark blue line, RXRa: green line) RMSD: 0.6A Right: Superimposition of 
3cbb (HNF4a DBD crystal structure) on to the DBD of the PPARy side of the heterodimer (3cbb: light 
blue line, PPARy: orange line) RMSD: 3.6A
The sequence of the full length HNF4a, the RXRa from the heterodimer (3dzy), the H NF4a 
DBD crystal structure (3cbb), the rat crystal structure of the HNF4a LBD (lm 7w) and the 
human HNF4a LBD model are aligned together; using Blosom62 (Gap start: 7 Gap Extend: 
1). This results in the alignment presented in Figure 78. The full length HNF4a sequence is 
included as an “empty sequence” with no structure that is used by MOE to build the model. 
Using this alignment to superimpose the structures, translates all coordinates associated with 
those aligned; preserving the quaternary structure (Figure 79).
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Figure 78: Alignment of template models for the first HNF4a monomer model based on the RXRa 
monomer (PDB code 3dzy). 1: Full length HNF4a sequence. 2: Sequence of the RXRa monomer from the 
PPARy-RXRa heterodimer (PDB code 3dzy). 3: Sequence from the crystal structure of the HNF4a DBD 
(PDB code 3cbb). 4: Sequence from the crystal structure of the rat HNF4a LBD (PDB code lm7w). 5: 
Sequence from the model of the human HNF4a LBD. Blue highlight: DBD sequences used to build the 
model. Pink highlight: LBD sequences used to build the model.
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Figure 79 Stereo view of the superimposition of the rat HNF4a LBD homodimer (PDB code lm7w) on to 
the coordinates of the RXRa coordinates (PDB code 3dzy) with the model of the human HNF4a LBD 
superimposed onto the coordinates of the rat HNF4a LBD homodimer (PDB code lm7w) according to the 
alignment presented in Figure 78. (See text) Green ribbons: DNA from 3dzy. Yellow ribbons: DNA from 
human HNF4a DBD (PDB code 3cbb). Red ribbons: RXRa and PPARy chains from 3dzy. Blue ribbons: 
human HNF4a DBD (PDB code 3cbb). Pink ribbons: rat HNF4a LBD homodimer (PDB code lm7w). 
Orange ribbons: model of the human HNF4a LBD.
Building of HNF4a monomer models based on RXRa and PPARy monomers
The first model built was of a single monomer of HNF4a based on the alignment presented 
in Figure 78 and the superimposition in Figure 79. Figure 80 shows the template structures on 
which the HNF4a monomer model is based, using the RXRa monomer from the RXRa- 
PPARy heterodimer as a template for the placement in space of the DBD and LBD in relation 
to each other and the rest of the structure. The sequences for the template structures were 
selected with the “empty” HNF4a sequence as per the blue and pink highlighting in Figure 
78. MOE’s homology modelling tool was then used to build the model. The tool was 
instructed to use the selected residues as a template for the model; the default settings of the 
homology modelling tool were used. This resulted in the output of a database of ten 
intermediate models refined using AMBER99 (10-12) to minimise the models to a gradient 
of 1 kcal/mol A, and a final model; minimised to a gradient of 0.5 kcal/mol A (Figure 81).
The second model of a HNF4a monomer was based on the PPARy monomer from the 
RXRa-PPARy heterodimer, the alignment shown in Figure 82 and the superimposition in
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Figure 79 were used to organise domains as a template for the model. The structures to be 
used as templates are shown in Figure 83, showing the structures for the different domains 
correctly orientated with respect to each other.
The second H NF4a model was constructed using the same methodology as the first model; 
this resulted in a database of ten intermediate models and a final model: presented in Figure 
84.
Figure 80: Stereo view of the template structures for the first HNF4a monomer, based on RXRa (from 
3dzy) for domain placement. Yellow ribbons: DNA strands from the HNF4a DBD crystal structure 
(3cbb). Blue ribbon: HNF4a DBD crystal structure (3cbb). Orange ribbon: model of the human HNF4a 
LBD.
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Figure 81: Stereo view of the final model of the HNF4a monomer based on the RXRa monomer from the 
RXRa-PPARy heterodimer output by MOE. (Monomer 1)
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Figure 82: Alignment of template models for the first HNF4a monomer model based on the PPARy 
monomer from 3dzy. 1: Full length HNF4a sequence. 2: Sequence of the PPARy monomer from the 
PPARy-RXRa heterodimer (PDB code 3dzy). 3: Sequence from the crystal structure of the HNF4a DBD 
(PDB code 3cbb). 4: Sequence from the model of the human HNF4a LBD. Blue highlight: DBD sequences 
used to build the model. Pink highlight: LBD sequences used to build the model.
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Figure 83: Stereo view of the template structures for the first HNF4a monomer, based on PPARy (PDB 
code 3dzy) for domain placement. Yellow ribbons: DNA strands from the HNF4a DBD crystal structure 
(PDB code 3cbb). Blue ribbon: HNF4a DBD crystal structure (PDB code 3cbb). Orange ribbon: model of 
the human HNF4a LBD.
Figure 84: Stereo view of the final model of the second HNF4a monomer based on the PPARy monomer 
from the RXRa-PPARy heterodimer output by MOE. (Monomer 2)
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C onstruction  of an HNF4a hom odim er bound to DNA
To construct the dimer, the two monomers to be used need to be determined. This is achieved 
by loading the models from the output databases resultant from the initial modelling and 
looking for any unfavourable conditions; such as chains or atoms clashing (sharing the same 
positions in space). In this case, the first model from the database based on the RXRa 
monomer (Monomer 1) was used in combination with the final model from the database 
based on the PPARy monomer (Monomer 2). The crystal structure of the HNF4a DBD (PDB 
code 3cbb) was added to the model in order insert the DNA strands and zinc ions that 
comprise part of the zinc finger motifs of the DBD. This results in an overall structure as 
shown in Figure 85, before the refinement of any outlying residues or atom clashes.
Figure 85: Stereo view of the overall structure of Monomers 1 and 2 combined to give the HNF4a 
homodimer bound to DNA before the refinement of outlying residues and atom clashes.
Analysis of the overall structure, for any unfavourable geometries; was conducted by 
inspection of the Ramachandran plot (Figure 86 example outlier: Ser321 labelled on plot). 
Outlying residues are treated on an individual basis. This is done by selecting the residue that 
is shown to be outside the expected bounds as defined by a Ramachandran plot, along with 
any residues with in a 4.5A distance of the outlying residue. An energy minimisation is 
performed to a target gradient of 0.05 kcal/mol A, on the selected atoms in order to relieve
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the unfavourable geometry. This refinement resulted in the majority of unfavourable 
geometries being modified to a more favourable conformation (Figure 87).
1 8 0  r  -
30 - g
-150 -
General Glycine
. .
%
TYR 319
SER KT
-150-120 -90 -60 -30 0 30 60 90 120 150 180
Phi
Proline
-150-120 -90 -60 -30 0 30 60 90 120 150 180
Phi
Psi
-150-120 -90 -60 -30 0 30 60 90 120 150 180
Phi
Pre-Proline180
150
120
90
-60
-90  -
-120
-150
-180
■150-120 -90 -60 -30 0 30 60 90 120 150 180
Phi
Figure 86: Ramachandran plot for the overall structure of the HNF4a homodimer bound to DNA before 
the refinement of outlying residues. Allowed regions: orange contours, Preferred regions: green contours. 
Red crosses (labelled): outlying residues.
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Figure 87: Ramachandran plot of the HNF4a homodimer model bound to DNA after the refinement of 
unfavourable geometries. Allowed regions: orange contours, Preferred regions: green contours.
Once unfavourable geometries (as defined from inspection of the Ramachandran plots Figure 
86) had been relieved, atom clashes (atoms sharing the same positions in space) between 
atoms resulting from the initial placement of the monomers during the construction of the 
homodimer were considered. These atom clashes were refined in much the same fashion as 
unfavourable geometries. Any atoms that were occupying the same spatial coordinates were 
selected with the atoms that comprise the residue they are a part of, and the selection 
extended to any residues with in 4.5A of the original residues containing the clashing atoms. 
An energy minimisation was performed on these selected atoms only, to a gradient of 0.05 
kcal/mol A.
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The zinc ions were inserted into the model as mentioned previously, these ions were then 
moved manually into a position where they are able to coordinate in as close to a tetrahedral 
configuration as possible with the sulphurs of the four cysteine residues with in each site. The 
charge on each zinc ion is set to 2+. MOE’s Protonate 3D tool was then used to protonate the 
system at physiological pH (pH 7.4) at 300K with default settings for the tool. The dielectric 
for the system was set to 4.0 with the solvent set to 80. The zinc atoms were then selected 
with any residues with in 4.5A, and the Protonate 3D tool used again with the same settings 
on these selected atoms, in order to allow all the atoms selected to allow the sulphurs of the 
cysteines to adopt a tetrahedral arrangement around their respective zinc ions. This resulted in 
the sulphur atoms on the cysteines being deprotonated and given a charge of -1.05.
Figure 88: Stereo view of the tetrahedral configuration of cysteine residues around a zinc ion.
The final items added to the model were the ligands; the ligands for this model are fatty acids, 
these are inserted into the model by using the crystal structure of the human HNF4a LBD 
(PDB code lpzl). The sequences were aligned with the sequence of the monomers that 
comprise the model; this was accomplished in the same manner as previously described, and 
superimposed on to the coordinates of the models. This results in the placement of the ligand 
native to the human HNF4a LBD, with in the ligand binding pocket of the model. The
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extraneous coordinates that accompany the ligand in the crystal structure of the human 
HNF4a LBD (such as solvent, co-regulator fragment and the LBD itself) were deleted, 
leaving the coordinates of the ligand in the correct position and orientation with respect to the 
rest of the LBD model. This is repeated for both monomers so that both the ligand binding 
pockets are occupied with the correct ligand in the same orientation as those in the original x- 
ray crystal structure.
The ligands were selected with the coordinates of the residues that comprise the binding 
pocket (residues that fall with in 4.5A of the ligand, completely or in part). MOE’s Protonate 
3D tool was used to add hydrogens to the selected atoms in the correct configuration for the 
systems pH (pH 7.4), these atoms are then minimised to a gradient of 0.05 kcal/mol A.
The final step to complete the overall model was an energy minimisation of the entire system 
to a gradient of 0.1 kcal/mol A. This lower gradient value was used here, as it was the whole 
system being minimised as opposed to a small area of the system. The final model is shown 
in Figure 89.
Molecular Dynamics of the HNF4a Homodimer Model
The starting point for the molecular dynamics calculation (Figure 89) was assessed for 
structural abnormalities using a Ramachandran plot, bond lengths and atom clashes. A good 
starting point is one where there are few outlying residues, bond lengths that are close to the 
expected average bond lengths for each bond type and few atom clashes; clashes including 
ionic interactions such those between the sulphur of a cysteine and a zinc ion are allowed.
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Figure 89: Stereo view of the final complete model of the HNF4a homodimer bound to DNA (amino acids 
49-369) with ligands bound to their binding pockets (Space fill).
The atoms associated with the DNA strands were tethered to their starting coordinates with a 
weighting of 500, in order to preserve the overall DNA structural bending as present in the 
template crystal structure (5).
The molecular dynamics calculation was performed using MOE’s molecular dynamics tool. 
The Nose-Poincare-Anderson (13) (NPA) algorithm was employed to perform the calculation 
using the NVT ensemble, where volume and temperature are kept as close to constant as the 
variation in the calculation will allow; this is accomplished by using weightings on these 
values. The weighting for the temperature was set to 0.05 giving tight control (14) over the 
value resulting in little variation in the calculated temperature.
The simulation was set to run for 1000 picoseconds (ps) or 1 nanosecond (ns), at a simulated 
temperature of 300K. Each step of the calculation is calculated every 0.00 lps (1 
femptosecond (fs)) and a snapshot of the simulation recorded every 0.5ps. These settings 
provide a stable simulation where there is little drift in the output value H, the gradient of the 
output against time is -0.00048, suggesting a stable simulation. This drift is calculated for the 
output values once the simulation has equilibrated, which is considered to be after the first 
lOOps of the simulation (Figure 90).
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The molecular dynamics simulation also outputs each conformational change at each 
snapshot, the final snapshot from the calculation after equilibration and 900ps of simulation is 
shown in Figure 91. During the running of the simulation conformational changes occur, 
causing momentary geometric strains (these occur for a time in the order of a few fs); these 
are shown in the Ramachandran plot (Figure 92). This plot shows many more outlying 
residues (e.g. Ilel75 labelled on plot) compared to that of the starting point for the simulation 
(Figure 89). This is due to the movement associated with the simulation and the increase of 
energy from the higher temperature the simulation is run at, this is opposed to that of the 
starting point; which is close an energy minimum. This allows strained geometries for 
moments in time.
To assess the structural difference between the output model from simulation and the original 
template structures, these template structures were superimposed onto the models 
coordinates. Superimposition of the crystal structure of the HNF4a DBD (PDB code 3cbb) 
on to the corresponding coordinates of the model gives a RMSD of 1.89A. Superimposition 
of the crystal structure of the human HNF4a LBD (PDB code lpzl) on to the model results in 
a RMSD of 3.32A for the monomer based on the RXRa monomer side of the dimer, and 
3.51 A for the PPARy monomer side of the dimer (Figure 93). These superimpositions of the 
original structures, show a small difference between the structures which is to be expected 
after equilibration and 900 ps of molecular dynamic simulation at 300K.
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Figure 90: Plot of the output from the molecular dynamics simulation ((H) Hamiltonian) vs. Time (t) in 
ps.
Figure 91: Final model output from the molecular dynamics simulation, zinc ions and ligands shown in 
space HU.
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Figure 92: Ramachandran plot for the output model from the molecular dynamics simulation. Allowed 
regions: orange contours, Preferred regions: green contours. Red crosses (labelled): outlying residues.
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Figure 93: Stereo view of the final HNF4a model output from the molecular dynamics simulation (Red 
and green ribbons) with the original HNF4a crystal structures superimposed. Yellow and brown ribbons: 
HNF4a LBD crystal structures (PDB code: lpzl) Light blue and orange ribbons: HNF4a DBD structure 
(PDB code: 3cbb)
Dimerization contact analysis for the HNF4a homodimer model from the 
molecular dynamics simulation.
The output database from the molecular dynamics simulation was used to analyse the most 
common protein-protein contacts with in the HNF4a homodimer model. The simulation was 
considered to be equilibrated after lOOps of calculation; samples were taken starting at the 
501st step in the calculation and every 250 steps after, equivalent to starting at 250ps with 
125ps intervals. This gives seven models with slightly differing structures, resulting in a 
range of conformational stages that mimic the dynamic nature of the complex, providing 
insight into which residues have regular interactions with other residues in the structure. In 
order to identify the most common interactions between the monomers, MOE’s contact 
analysis tool was used to highlight sidechain to sidechain interactions. For each of the seven 
sample models, the recorded contacts were split into one of four categories:
• reported contacts: contacts between residues that have been reported in the literature;
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• Unreported contacts: contacts between residues that have not been reported in the 
literature;
• reported and unreported: reported residues reported to contact their reported residue, 
contacting a residue that has not been reported to contact any residues;
• reported to other reported: residues that have been reported to contact a particular 
residue contacting another residue reported to contact another particular residue.
These contacts are subdivided by their interaction type: hydrogen bonding, hydrophobic and 
ionic. Interactions are ranked according to their occurrence out of the seven samples. If an 
interaction occurs multiple times with in a group of samples, it is considered a likely common 
interaction between the monomers. Tables 1-9 contain the interactions between the 
monomers and their occurrence in the samples investigated, Figure 94 shows all the 
interactions present in the dimerization interface between the two HNF4a monomers. 
Mutations leading to diabetes MODY or MODY1, are marked in bold (Tables 1-9) as 
identified in the Human Gene Mutation Database (75).
Figure 94: Stereo view of the dimerization interface between the two monomers that comprise the 
heterodimer (Final out put model of the simulation). Carbons are coloured to match their respective 
ribbons.
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Table 16: Unreported hydrogen bonding contacts ranked according to occurrence (Bold: mutation)
Residue 1 Residue 2 Occurrence
Arg168 Gln92 1/7
Asp232 Lys109 1/7
Asp98 Gln122 1/7
Gln271 Gln122 1/7
Gln318 Asn315 1/7
Gln347 Gln347 1/7
Gln347 Gln362 1/7
Gln362 Gln345 1/7
Glu217 Ser337 1/7
Lys291 Ser337 1/7
Lys350 Gln347 Ml
Ser337 His214 Ml
Gln362 Gln347 2/1
Glu363 Gln345 2/7
Lys231 Ser78 2/7
Ser161 Glu119 2/7
Arg301 Asp320 3/7
Asn101 Arg125 3/7
Glu334 Gln362 4/1
Asp289 Thr334 5/7
Asp98 Asn123 5/7
Glu363 Arg254 5/7
Thr334 Asp289 5/7
Asp166 Arg113 7/7
Glu344 Lys291 7/7
Lys291 Glu344 7/7
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Table 17: Unreported hydrophobic contacts ranked according to occurrence
Residue 1 Residue 2 Occurrence
Phe348 Phe352 1/7
Leu351 Leu351 2/7
Leu351 Phe348 2/7
Leu351 Phe352 3/7
Ile167 Phe112 5/7
Phe348 Leu351 5/7
Phe230 Phe112 7/7
Val264 Val79 7/7
Table 18: Unreported ionic contacts ranked according to occurrence (Bold: mutation)
Residue 1 Residue 2 Occurrence
Arg301 Asp320 3/7
Asp232 Lys109 3/7
Glu363 Arg254 5/7
Asp166 Arg113 7/7
Glu344 Lys291 7/7
Lys291 Glu344 7/7
Table 19: Reported and unreported hydrogen bonding contacts (Bold: mutation)
Residue 1 Residue 2 Occurrence
Glu262 Lys300 Ml
Glu269 Arg301 Ml
Glu344 Gln362 1/7
Ser337 Gln336 Ml
Arg88 Ser129 2/7
Gln102 Asn123 2/7
A sp303 Thr334 3/7
Gln268 Glu124 3/7
Gln102 Arg127 4/7
Ser321 Glu311 4/7
Asp137 Arg322 5/7
Ser86 A sp126 5/7
Arg104 A sp126 6/7
Glu269 Arg127 6/7
Ser304 Glu327 6/7
Arg301 Glu269 6/7
Thr334 Lys300 7/7
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Table 20: Reported and unreported hydrophobic contacts (Bold: mutation)
Residue 1 Residue 2  Occurrence
Ile314 Phe325 5/7
Phe325 Leu310 5/7
Trp340 Leu366 5/7
Ile343 Trp340 7/7
Table 21: Reported and unreported ionic contacts (Bold: mutation)
Residue 1 Residue 2 Occurrence
Glu269 Arg301 2/7
Glu262 Lys300 3/7
Arg301 Glu269 6/7
Glu269 A rg127 7/7
Arg104 A sp126 7/7
Asp137 Arg322 7/7
Table 22: Reported hydrogen bonding contacts (Bold: mutation)
Residue 1 Residue 2 Occurrence
Lys300 Glu269 1/7
Glu327 Lys300 4/7
Arg322 Asp312 5/7
Arg88 A sp126 5/7
Arg303 Glu327 6/7
Asp312 Arg322 6/7
Glu327 A rg303 7/7
Lys300 Glu327 7/7
Table 23: Reported hydrophobic contacts (Bold: mutation)
Residue 1 Residue 2 Occurrence
Leu332 Leu330 5/7
Leu329 Leu329 6/7
Ile283 Leu330 7/7
Leu330 Ile283 7/7
Leu330 Leu332 7/7
Phe325 Phe325 7/7
T rp340 Trp340 7/7
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Table 24: Reported ionic contacts (Bold: mutation)
Residue 1 Residue 2 Occurrence
Lys300 Glu269 2/7
Arg88 A sp126 6/7
Glu327 Lys300 6/7
A rg303 Glu327 7/7
Arg322 Asp312 7/7
Asp312 Arg322 7/7
Glu327 A rg303 7/7
Lys300 Glu327 7/7
Table 25: Reported and other reported contacts (Bold: mutation)
Type Residue 1 Residue 2 Occurrence
HB Arg322 Glu311 1/7
HB Glu311 Arg322 3/7
HYD Leu329 Leu330 5/7
HYD Leu330 Leu329 6/7
ION Arg322 Glu311 4/7
ION Glu311 Arg322 5/7
Table 26: Reported dimerization interactions (Dhe-Paganon et al. 2002 & Lu et al. 2008)
Residue 1 Residue 2
A sp126 Arg88
Gln307 Glu327
Glu311 Gly323
Gln336 Gln336
Phe325 Phe325
Leu329 Ieu329
Leu330 Ile283
Leu332 Leu330
Pro333 Pro333
Trp340 Trp340
Glu269 Lys300
Arg303 Glu327
Arg322 Asp312
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Discussion
The model shows a number of novel interactions between the two monomers, including a 
new point of dimerization. Figure 95 shows such a dimerization interface between the LBD 
and DBD.
The dimerization surface between the DBD of one monomer and the LBD of the other is 
placed at a critical position in relation to the rest of the complex. There are three common 
interactions in this region: The hydrophobic interactions Val79:Val264 and Phell2:Phe230 
and the ionic interaction: Aspl66:Argll3. The proximity of these contacts to the ligand 
binding pocket (Figure 95) suggests changes in this region will cause conformational changes 
to the structure of the ligand binding site. Such changes would doubtless change the way in 
which the ligand acts on the complex. The novel interface contains the residue Phell2 which 
is part of an hydrophobic cluster known to be destabilised by the phosphorylation of Ser78, 
this phosphorylation prevents DNA binding (16). It is now clear that not only will this 
phosphorylation abolish DNA binding but may also disrupt the interface between the DBD 
and LBD.
Contacts between the two monomers forming dimerization interactions are of interest. 
Mutations at these points are likely to cause inactivation or modification of the way in which 
these monomers interact. The residues that are known to mutate are in bold text in Tables 1-9. 
Residues that are not in bold (Tables 1-9) represent points at which a potential interaction 
could be disrupted should a mutation take place, leading to possible inactivation or 
modification of action of the complex. An example of this is the ionic interaction of Lys291 
and Glu344. The location of the Lys291:Glu344 interaction is at the dimerization interface of 
the LBDs of the homodimer which is not seen in the crystal structure of the HNF4a LBD 
homodimer (rat: PDB code lm7w). These residues in the crystal structure are separated by 
11.5A and 12.96A (Figure 96). However in the final model output from the molecular 
dynamics simulation; the distance has closed to less than 4A (Figure 97). This is due to 
equilibration to a stable range of conformations of the protein complex at 300K and settling 
of the structure under these conditions. In a higher energy system such as the conditions 
under which this complex exists, there may be greater movement and contraction of the 
structure; which would not be present in an x-ray crystal structure.
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Phe230
Asp166
Val264
Phe112
Val79
Arg113
Figure 95: Novel dimerization interface between the DBD and LBD of the two monomers with in the 
HNF4a homodimer bound to DNA. Common interactions shown, residues coloured dark green: aliphatic, 
green: aromatic, red: acidic, blue: basic.
The proximity of these residues may only be a feature of the truncated form of the sequence. 
A repressor domain present towards the C-terminus of the F-domain (aa: 430-441); aligns
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with a similar region with in PR (progesterone receptor) (77) that may bind between 
monomers with the PR structure (78). This inhibition is demonstrated with a structural 
overlay of the PR LBD structure (PDB code: la28) onto the coordinates of the rat HNF4a 
LBD (Figure 98). If this is also the case with the HNF4a homodimer structure, then it would 
show that the interaction Lys291:Glu344 helps enhance transcription. However this is 
inhibited by this repressive domain bound between the monomers at the point at which these 
residues would make contact with each other. This would explain how the reported repressor 
region reduces the transcriptional activity of HNF4a.
Figure 96: Stereo view of the distance between Lys291 and Glu344 with in the crystal structure of the rat 
HNF4a LBD homodimer (PDB code: lm7w).
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Figure 97: Stereo view of the distance between Lys291&Glu344 with in the final model of the HNF4a 
homodimer from the molecular dynamics calculation.
Figure 98: Stereo view of the overlay of the PR crystal structure (Pink ribbon) on to the HNF4a rat 
homodimer (PDB code: lm7w, Green & Red ribbons) Yellow Ribbon: Repressor region on the PR 
structure. Overlay RMSD: 4.4A.
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Models comparison
The model presented in this chapter (Model 2) is based on a more complete template than that 
of the previous chapter (Model 1). This suggests that the structure will be more representative 
of the natural form. The major difference between these two models is the orientation of the 
LBD with respect to the DBD. A rough manual overlay of the DBDs from both models 
shows that the LBDs are on opposite sides of DNA with respect to one another (Figure 99). 
In model 1 the LBD is modelled with the ends of the hinge region being as close to the 
corresponding ends of the hinge region associated with the DBD as depicted in Chapter 3 
Figure 50; however this is not the case for model 2. The orientation of the LBD in model 1 
excludes the novel dimerization interface between the LBD and DBD as presented in model 
2, where the area close to the ligand binding pocket forms a hydrophobic association with the 
DBD (Figure 95). The orientation of the LBD in model 2 is also more logical from the point 
of view of how information is transferred between the domains. In model 2 there is a defined 
dimerization interface; however in model 1 there is merely a hinge region between the LBD 
and the DBD to the LBDs on the other side of the DNA double helix.
Figure 99: Rough manual overlay of the DBDs from models 1 & 2 showing the LBD orientations. Green 
& Light Blue Ribbons: Model 1. Pink & Red Ribbons: Model 2.
In this chapter a model of the DBD and LBD from the HNF4a homodimer bound to DNA, 
was constructed based on the crystal structure of the RXRa-PPARy heterodimer. This model 
was used as a starting point for a molecular dynamics simulation. After equilibration a stable 
simulation resulted. This was examined to derive a number of previously unseen interactions
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between the two monomers that form the homodimer. This included a novel dimerization 
interface between the DBD of one monomer and the LBD of the other. Phosphorylation of a 
nearby residue is likely to disrupt this novel interface as well as the complexes ability to bind 
DNA.
Interactions previously not seen to occur due to the rigid nature of crystal structures were 
observed. In some cases these interactions may be prevented by the placement of a reputed 
repressor domain found at the c-terminus of the F-domain.
Mutations recorded in the Human Gene Mutation Database (15) were identified in the 
observed interactions, going some way to explaining their effect on the system.
Overall the model presented here is an improvement on the model presented in the previous 
chapter, due to being based on a more complete template structure.
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Inhibition of ATP Synthase: The binding of oligomycin
The solution of the single crystal x-ray structures of oligomycins A, B and C by our 
collaborators (1) has enabled the use of the actual three dimensional structures of oligomycin 
as probes to computationally dock into a model of E. Coli ATP Synthase, which was built by 
protein homology modeling. The protein model as built did not have a suitable pocket for the 
oligomycins to bind, so an induced fit energy minimsation method was used to prepare a 
suitable site. Docking of oligomycin to this pocket provides: 1) insight into how oligomycin 
inhibits ATP Synthase; 2) interactions which are found between amino acid residues known 
to be involved in oligomycin binding from experimental data with the bound oligomycins; 3) 
calculated values of the inhibition constants (Ki) of the oligomycins that compare with 
experimentally measured values.
Oligomycin Structures
Oligomycin was crystallised in three distinct forms, A, B and C (7); these differ from each 
other chemically only in one or two substituents (Figure 100). Experiments using oligomycin 
as a probe, do not usually attempt to distinguish between different forms of oligomycin, and 
often use the unrefined mixture of all three.
Figure 100: The three forms of oligomycin as crystallised. Solvent crystallized with the A and B forms, 
methanol and ethanoic acid respectively. (1)
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Oligom ycin A s truc tu ra l abnorm alities
Inspection of the oligomycin structures reveals that the A form contains an abnormal 
structural feature (Figure 101).
The geometries around this feature do not seem to conform to conventional chemistry; it 
would appear that the central bond (C2-C3: 1.44A (Table 27)) is considerably shorter than 
the average carbon-carbon single bond (normally about 1.54 A (2)) and is only comparable to 
a C-C with double and or triple bonds to carbon and or nitrogen, suggesting a significant 
amount of conjugation throughout the bond. The bond is also not short enough to be a double 
bond as there appear to be no instances of double bonds being stretched this far (2). 
Compounding this issue; C3 would appear to be flat planar (sp2) in nature where as C2 seems 
to be tetrahedral (sp3) and missing its fourth substituent, the angles leading to this conclusion 
are shown in Table 28 and displayed in Figure 101.
Table 27: Bond lengths present in oligomycin A (Figure 101)
Atoms Bond lengths (A)
C1-C2 1.54
C2-C3 1.44
C2-02 1.48
C3-C4 1.54
Table 28: Bond angles present in oligomycin A (Figure 101)
Connectivity Angle
C1-C2-02 110.0
C1-C2-C3 110.5
C3-C2-02 104.2
C2-C3-H3 118.5
H3-C3-C4 118.5
C2-C3-C4 123.0
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Figure 101: Oligomycin A with magnified stereo view of the structural abnormality. Solvent molecule 
(methanol) crystallised with the structure. Bond angles shown.
To investigate this abnormal geometrical feature an ab-initio calculation was performed to 
view the molecular orbitals surrounding these features. A fragment of the whole structure was
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used in order to focus the calculation around the feature and to reduce computation time 
(Figure 102).
The calculation was performed using the Hartree-Fock method with default spin and the 3- 
21G basis set.
Figure 102: Full structure of oligomycin A (Left) vs fragment (Right). Red circles indicate points at which 
the fragment was joined to the rest of the structure.
Figure 103: Views of different sides of the HOMO as calculated by Gaussian
This calculation resulted in the calculated HOMO of the fragment centring on the bond in 
question (Figure 103). The orbital appears to involve a form of a twisted n system. Such 
systems have only been observed in systems where there is extreme steric hindrance in a 
conjugated n  system causing a central bond to twist (3-5).
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Delocalisation of electrons throughout the bond would suggest a shortening of the C2-C3 
bond length, as is the case here; however due to the sp3 geometry of the C3 carbon it prevents 
a full double bond being formed. It is almost as if the double bond is about to form, this may 
be the result of a stabilising effect arising from the crystal nature of the system.
Oligomycin forms for docking
The bond between C2-C3 is shown to be too short to be considered as a single bond, and too 
long to be considered as a double bond. With this in mind it was decided to use two forms of 
oligomycin A in the docking study. One form is considered to have a single bond between 
C2-C3 (A), the other with a double bond between C2-C3 (A=). The other forms will remain 
as defined in their X-ray crystal structure (Figure 104).
025 025
A= HO
,0  030
OH O OH
024 026 028
.OH 032
H 037
014 .  0 0 3 6
09 9 H 0 2
HO
0030
iOH 032OH O 
024 026
OH
028
H 037
014 JL 0 036 
‘Oo9 OH 02
025
HO
0030
OH O OH
024 026 028
.OH 032
014 ^  0 0 3 6  
09 OH °2
0 7 0 .
OH 0 OH
024 026 028
.OH 032
H 037
014
0 0 3 6  
O H  02
Figure 104: Oligomycin forms for docking. Groups involved in binding to the receptor labelled.
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Modelling the E. Coli ATP Synthase F0 domain
The structure derived from NMR data and provided in the EBI (European Bioinformatics 
Institute), PDB entry code lc l7  (6) does not contain the section with residues numbered 167- 
198 in the a-subunit. The full sequence for this subunit was submitted to the SWISSMODEL 
(7) homology modelling server (www.expasv.org) and the resulting model had this section 
included. The model provided by SWISSMODEL was superimposed on to the coordinates of 
the same subunits in lc l7  using MOE (molecular operating environment, version 2007.09. 
Chemical Computing Group Inc.: Montreal, Quebec, Canada.) and an energy minimisation 
(The method of minimisation is dependant on the size of the RMS gradient, at higher 
gradients: Steepest Decents then Conjugate Gradients and at finer gradients: Truncated 
Newtonian) of the three chains involved in ligand binding was carried out until no van der 
Waals contacts were visible. Two models which were used for the docking were created from 
the resultant model, one containing the full twelve c-subunits (Model 1, Figure 105) the 
other; with the three subunits involved in binding with the ligand (Model 2, Figure 106).
Figure 105: Model 1: The Fo domain of E. Coli ATP Synthase containing the full c-subunit ring
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Figure 106: Model 2: Fragment of the Fo domain including the three subunits involved in ligand binding 
(subunit a and two c-units from the ring).
An induced fit model of the E. Coli ATP Synthase F0 domain, for the docking of 
oligomycins.
Owing to the lack of a large enough space between the subunits thought to be involved in the 
binding of oligomycin, there was the need to create a pocket into which to dock the ligand. A 
small space at the desired location was found using Site Finder in MOE and dummy atoms 
were placed into this pocket. Oligomycin B was then manually overlaid on to these dummy 
atoms and an energy minimisation was carried out using AMBER99 (8) the three chains 
involved in binding (two c-subunits and the a-subunit). The backbone atoms of these chains 
were tethered with a default weight of 100 in order to keep the structural integrity of the
o
overall structure, and an RMS gradient of 0.1 kcal/mol A was applied to the calculation. The 
RMS gradient is a cut-off based on the gradient of the calculation and the number of unfixed 
atoms the calculation is based on. The energy minimisation was carried out twice more after 
termination of the calculation (RMS gradients 0.1 kcal/mol A and 0.05 kcal/mol A 
respectively) to eliminate disagreeable geometries. These included bond lengths greater than 
the average for each bond type, and the macrocyclic ring of the ligand (oligomycin B) 
positioning itself around a helix (remedied by moving the ring atoms back to the pocket side 
of the helix manually and further energy minimisation). This resulted in a converged energy 
minimisation. In order to introduce diversity into the shape of the binding site and to allow
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for the other forms of oligomycin, oligomycin A was overlaid on to the coordinates of the 
energy minimised ligand (oligomycin B) with in the pocket; a further energy minimisation 
was performed using the conditions stated above. This procedure was followed during the 
creation of the pocket in both Model 1 (twelve c-subunits and one a-subunit (Figure 105)) 
and Model 2 (subunits involved in ligand binding (Figure 106)).
Verification of these models was carried out using PROCHECK (9) showing that more than 
90% of residues fell with in the most favoured regions of Ramachandran plots (Figure 107 & 
Figure 108).
Phi (degrees)
Figure 107: Ramachandran plot for Model 1 according to PROCHECK, outliers labelled in red.
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Phi (degrees)
Figure 108: Ramachandran plot for Model 2 according to PROCHECK, outliers labelled in red.
Similarity between the PDB starting model (PDB code lc l7 ) and the two models was 
calculated as an RMSD on a chain-by-chain basis for the three chains involved in binding 
only (Table 29).
Table 29: RMSD in A between each subunit involved in binding to oligomycin in each model and the 
template model (PDB code lc l7 ). Subunit identification according to Figure 110.
Model 1 RMSD all atoms Model l:a Model l:c l Model l:c2
lcl7:a 0.663
lcl7 :cl 0.576
Icl7:c2 0.716
Model 2 RMSD all atoms Model 2:a Model 2:cl Model 2:c2
lcl7:a 0.899
lcl7:cl 0.631
Icl7:c2 0.767
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Docking of Oligomycin to E. Coli ATP Synthase F0
Site Finder in MOE was used to place dummy atoms into the oligomycin binding pocket as 
the region to dock the ligand atoms with in the models (Figure 109). The placement method 
used was MOE’s Alpha Triangle method and the scoring was the London dG method. Each 
run was instructed to retain 200 docked conformations as a cut-off, unless it reached the 
timeout limit of 600 seconds. If the timeout was exceeded without the required amount of 
results, the docking calculation was rerun until at least 200 conformations made hydrogen 
bond contacts with the receptor. The top 200 resulting bound conformations were retained for 
analysis for each oligomycin type per model.
In the X-ray structure of oligomycin A (7) the side-chain carrying OH(02) (see Figure 104 
for numbering of hydrogen bond donors/ acceptors on the oligomycin forms for docking) 
forms a closed ring H-bond with 0 (09) in ring X and there is a single proton on C(3) of this 
side chain as opposed to two in oligomycins B and C. The bond length C(2)-C(3) (Figure 
101) in oligomycin A = 1.44 A is intermediate between single and double and is the only 
unusual bond in all thee structures. Since the force fields used in MOE are not parameterized 
for unusual bond geometries, it was necessary to dock two forms of oligomycin A: one where 
an extra hydrogen was added, creating a form with a single bond (denoted model A) and a 
second where C(2)=C(3) was constrained as a double bond (denoted model A=) (Figure 104). 
All four oligomycin forms (A, A=, B and C) were docked to the Fo site in turn.
For each of the four types of oligomycin that were docked, the following information was 
recorded for each contact made with the protein (more than one in some cases):
• residue type, number and subunit (subunit according to Figure 110);
• bonding type (backbone acceptor/ donor, H-bond acceptor/ donor (sidechain));
• distance between donor and acceptor as calculated by MOE (A);
• contact point on the ligand according to the numbering scheme Figure 104.
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Dummy atoms 
placed at the 
oligomycin 
binding site
Figure 109: Top: Model 1 with dummy atoms (Black) placed in the binding site for docking. Bottom: 
Model 2 with dummy atoms (Black) placed in the binding site for docking.
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c-unit, assigned: "c2"
Figure 110: Subunit assignment for the binding site of oligomycin with in the F0 of ATP Synthase.
Ligand Binding Site
c-unit, assigned: "c1"
a-subunit, assigned: "a"
Oligomycin is capable of binding to essential residues required for proton 
transport on different subunits of ATP Synthase
The binding of oligomycin to the three subunits involved in the protonation / deprotonation 
that results in the rotation of the c-subunit ring, this causes the rotation of this complex to 
stop, due to binding of oligomycin to the residues responsible for the translocation of protons. 
The sheer bulk of the ligand would also be a factor here, as it acts as a “stick in the spokes” 
preventing rotation.
The two models created here produced differing results with respect to the binding constants, 
which is due to two main factors: 1) Model 1 comprised the full Fo domain including all 12 
c-subunits and the a-subunit, whereas Model 2 consisted of the three subunits that encompass 
the oligomycin binding site. 2) The method used to create the binding pocket was 
purposefully flexible in order to introduce an element of randomness into the system. Thus,
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the calculated values for binding energies and inhibition constants are more useful as an 
indicator as to which of the oligomycin types has a greater affinity for the receptor. 
Experimental Ki values for oligomycin bound to ATP Synthase range widely; reported values 
are for various types of mitochondrial ATP Synthase and not the bacterial version. Values 
range from 0.0065pM in Mg2+ ATP Synthase (10) to 26pM in clathrin-coated vesicles for rat 
liver (11). A smaller range was reported for bovine heart mitochondria 0.1 -  0.6 pM (12). 
This is for a mixture of the different types of oligomycin; calculated Ki values for the mixes 
and individual oligomycin forms are reported in Table 30 and Table 31. The high end values 
for the mixture of oligomycins from Table 30 and Table 31 correlate with the experimental 
measurements. The Ki data indicates that the B and C forms bind better than the A form, 
however the A form dominates as it is in much greater abundance of concentration than the 
others in the ratio 75:10:8 as determined by HPLC (13).
Table 30: Calculated Ki values per oligomycin Model 1
Type From Ki (pM) ToKi (pM) Average Ki (pM)
A 5.16 x 1 0 12 9.269 X i ( r 1.554 X 10*
A= 8.205 x 10‘12 9.203 X iff2 4.857 X 10‘6
B 5.157 x Iff13 1.244 X icr1 6.146 X 10'7
C 3.942 x Iff15 3.801 X Iff3 7.522 X 10'9
Mix (A) 3.922 x 10‘12 1.124 X 10‘3 1.228 X 10*
Mix (A=) 6.206 x Iff12 6.945 X Iff2 3.705 X 10'6
Table 31: Calculated Kx values per oligomycin Model 2
Type From Ki (pM) To Ki (pM) Average Ki (|iM)
A 4.398 X 10'11 4.028 xlO'1 4.295 x Iff4
A= 1.431 X 10'10 3.134 3.22 x Iff4
B 1.433 X 10'12 5.199 5.207 x 10^
C 4.972 X io-13 10.59 6.073 x 10-6
Mix (A) 3.317 X 1 0 n 1.669 3.747 x Iff4
Mix (A=) 1.075 X 10'10 3.718 2.94 x 10^
Individual AG values indicate that all oligomycin types have greater affinity to Model 1 than 
to Model 2 (average AG < 0 kcal/mol); this could be due to the missing subunits in the 
second model and shows that in general it is better to use a more complete model. This does
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not completely invalidate the second model however, as it can be used in combination with 
the first model to indicate how the ligand may contact the protein.
The docking studies performed have highlighted contacts to the following residues that are 
known to be essential for proton transport through the membrane: Asp61, Arg210, Asn214 
and Gln252 (14). Figure 111 and Figure 112 demonstrate oligomycin C bound in place, 
contacting these integral residues.
Figure 111: Stereo view example of docking results: oligomycin C docked AG -2650 cal/mol, KYi 1.17xl0-7 
pM.
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O polar * sidechain acceptor O  solvent residue 
O  acidic * sldechain donor O m etal complex 
O basic  • ► backbone acceptor solvent contact 
O greasy  *  backbone donor melal contact
proximity ^  ligand q  receptor
contour exposure ^ e x p o s u r e
Figure 112: Ligand interaction diagram of oligomycin C bound to ATP Synthase.
According to the docking study these residues were contacted preferentially by specific 
ligating groups on the antibiotic. The ligating group that appears to be most essential to 
binding is 024 with a preference for Asn214; this is a consistent theme for all forms of 
oligomycin and with both models. Furthermore the results indicate that the ligand has a 
tendency to arrange itself in such a way that the outer ligating groups (024, 028, 032  and 
014) are positioned such that they will coordinate with Asn214, similar to the way 
oligomycin A was calculated to act with divalent metal cations (75). This allows for a certain 
amount of mobility with in the pocket permitting the ligating groups to contact other residues, 
for example 028 — Gln252 and 0 2  — Asp61. Top ligand contacts for each oligomycin are 
reported in Table 32 and Table 33.
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Table 32: Top ligand contacts from docking runs for each oligomycin model (A, A=, B, C) with full Fq
model (Model 1). See Table 34 for total number of contacts to the protein.
Ligating
group
Main protein 
contact
Total number of 
contacts to protein % of total contacts
A
024 Asn214 87 24.72%
0 2 Ile248 75 21.31%
028 Gln252 66 18.75%
036 Gln252 54 15.34%
A=
024 Asn214 88 30.56%
028 Gln252 60 20.83%
036 Gln252 55 19.10%
B
024 Asn214 111 34.37%
028 Gln252 50 15.48%
032 Alal3c2 36 11.15%
C
0 2 Ile248 172 53.25%
024 Asn214 73 22.60%
014 Asn214 34 10.53%
036 Gln252 29 8.98%
Table 33: Top ligand contacts from docking runs for each oligomycin model (A, A=, B, C) Model 2. See
Table 34 for total number of contacts to the protein.
Ligating
Group
Main protein 
contact
Total number of 
contacts to protein % of total contacts
024 Asn214 90 24.32%
0 2 Asp61c2 58 15.68%
A 028 Gln252 54 14.59%
032 Asp61c2 54 14.59%
025 Gln252 49 13.24%
024 Asn214 125 36.23%
032 Asp61c2/Gln252 52 15.07%
A= 028 Asn214 51 14.78%
025 Asn214 31 8.99%
014 Asn214 28 8 .12%
024 Asn214 120 32.43%
0 2 Gln252 52 14.05%
B 07 Asn214 38 10.27%
028 Asn214 35 9.46%
032 Gln252 33 8.92%
024 Asn214 103 32.19%
0 2 Arg210/Val60cl 62 19.38%
C 014 Asn214 54 16.88%
032 Gln252 36 11.25%
028 Asn214 29 9.06%
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Table 34: Number of docked conformations with contacts to the protein
Model 1
Oligomycin type: Number of bound conformations Total number of contacts:
A 200 325
A= 200 288
B 200 323
C 200 329
Model 2
Oligomycin type: Number of bound conformations Total number of contacts:
A 200 370
A= 200 345
B 200 370
C 200 320
The main residues that are contacted by the oligomycins are shown in Figure 113 and Figure 
114.
Figure 113: Stereo view of the top residues involved in ligand binding, Model 1. Residues coloured 
according to function: Red: acidic, Blue: basic, Pink: neutral hydrophilic, Green: aliphatic.
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Figure 114: Stereo view of the top residues involved in ligand binding, Model 2. Residues coloured 
according to function: Red: acidic, Blue: basic, Pink: neutral hydrophilic, Green: aliphatic.
The top five residues contacted by the oligomycin forms account for about 75% of the total
contacts made, suggesting a preference for these residues for binding. These top five are 
shown in Table 35 and Table 36.
Table 35: Top five residues contacted by the oligomycin forms, Model 1.
Oligomycin
type: Residue
% of
total
contacts
Residue
% of
total
contacts
Residue
% of 
total 
contacts
Residue
% of 
total 
contacts
Residue
% of 
total 
contacts
A Gln252a 28 Asn214a 22.2 Asp61cl 11 Ile248a 7.4 Leu251a 3.4
A= Gln252a 26.4 Asn214a 26 Asp61cl 11.8 Pro64cl 5.9 Ile248a 5
B Asn214a 39.3 Gln252a 13.6 Alal3c2 9 Val60cl 7 Pro64cl 4
C Asn214a 31.3 Gln252a 17 Ile248a 15 Asp61cl 7.6 Leu251a 7.6
Table 36: Top five residues contacted by the oligomycin forms, Model 2.
Oligomycin
type: Residue
% of
total
contacts
Residue
% of
total
contacts
Residue
% of 
total 
contacts
Residue
% of
total
contacts
Residue
% of 
total 
contacts
A Asn214a 32.4 Gln252a 18.4 Asp61c2 12.2 Arg210a 6.8 Pro64c1 6.2
A= Asn214a 40.6 Gln252a 17.9 Asp61c2 11 Pro64c1 5.5 Arg210a 4
B Asn214a 45 Gln252a 16.2 Asp61c2 6.8 Pro64c1 4.3 Arg210a 4
C Asn214a 51.9 Gln252a 12.8 Arg210a 6.6 Val60cl 5.6 Asp61 c 1 3.4
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Many of the same top residues that bind to oligomycin forms in the two models are the same 
as those known to be involved in proton transport through the membrane. These residues 
include Asn214, Asp61 and Gln252 (6, 14, 16, 17). Another residue that is commonly 
reported to be integral to proton transport across the membrane is Arg210 (6, 14, 16, 18-20), 
this residue is contacted more regularly in Model 2 than in Model 1.
On the whole these data shows that oligomycin acts in more than one way to inhibit ATP 
synthesis; primarily by binding to the essential residues required for proton transport across 
the membrane and preventing their protonation and or deprotonation. As a secondary result of 
binding to these residues on different subunits, oligomycin essentially binds the c-units to the 
stationary a-subunit preventing rotation of the c-ring and thus preventing ATP synthesis. The 
sheer bulk of oligomycin could also be a factor as it could prevent rotation by acting as a 
“stick in the spokes” of the rotor (Figure 115).
Figure 115: Stereo view of oligomycin C (space fill) bound to Asn214 and Asp61c2 (Hydrogen bonds: pink 
dotted lines). This demonstrates how oligomycin binds to proton translocating residues on different 
subunits binding them together; preventing rotation, and how the bulk of the ligand would interfere with 
rotation. (K! of bound oligomycin C in this image: 5.9xlO'I3pM, AG -9920 cal/mol)
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Conclusions
Previous to this work on the modelling of HNF4a, the available x-ray crystal structures were 
of the individual LBD and DBD, not of the full length sequence’s structure. During the time 
in which this work was carried out, a structure of the heterodimer of PPARy-RXRa with both 
their LBD and DBD was crystallized. This structure was used as a template for the modelling 
of an HNF4a model that comprises both the LBD and DBD as two monomers complexed as 
a homodimer.
Modelling of the HNF4a truncated homodimer (amino acids 49-369), has revealed some 
interesting insights into its structure and the interactions between its constituent amino acids. 
In particular those involved at the dimerization interface. Further to this, a novel dimerization 
surface was shown to exist between the DBD of one monomer and the LBD of the other. This 
new dimerization surface has revealed three main interactions that contribute to holding the 
two domains of the two monomers together and is likely to be involved in the way in which 
the DBD may influence ligand binding in the LBD and vice versa. A phosphorylation point at 
Ser78 with in the DBD that is reported to abolish DNA binding, affects the region of the 
DBD that is in contact with the LBD.
Examination of interactions at the dimerization interface of the LBD reveals interactions that 
are not present in the crystal structure such as that between Lys291 and Glu344, which were 
revealed after the molecular dynamic equilibration. This shows that the rigid and low energy 
nature of the crystal structure is possibly insufficient to observe the full scope of interactions 
with in the structure. One inference that may be made from this interaction is that the 
repressive function of the repressor domain (amino acids 430-441) is potentially due to the 
separation of these residues, as this interaction occurs in the location where the repressive 
domain could interact with the rest of the structure.
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Figure 116: Model of HNF4a homodimer as based on the PPARy-RXRa heterodimer before the 
molecular dynamics simulation
Figure 117: Model of HNF4a homodimer as based on the PPARy-RXRa heterodimer after the molecular 
dynamics simulation
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There are numerous mutational studies of the binding site of the antibiotic oligomycin with in 
the Fo domain of ATP Synthase; investigated due to the apparent “oligomycin resistance” 
provided by these mutations. With the x-ray crystallization of the three forms of oligomycin 
and models of the ATP Synthase Fo domain available, it was possible to perform docking 
simulations of the oligomycin structures, in order to provide insight into exactly how 
oligomycin binds to ATP Synthase.
The docking of the three forms of the antibiotic oligomycin to a model of the ATP synthase 
Fo domain has given insight into how oligomycin inhibits the synthesis of ATP.
Oligomycin binds to the essential residues required for the translocation of protons across the 
membrane. These residues include those amino acids that transfer protons from a stationary 
subunit (subunit a), to a set of moving subunits (the c-ring). This includes the residues 
Asn214, Gln252 and to a lesser extent Arg210, which are part of the proton channel in the 
stationary subunit a. The main residue contacted by oligomycin in the rotating c-ring is 
Asp61, which is protonated by Arg210 and carries the proton round while the c-ring rotates. 
This modelling work has shown that oligomycin prevents the synthesis of ATP by a 
combination of three mechanisms: 1) Proton translocation is blocked by oligomycin binding 
to the residues that are responsible for the movement of the proton across the membrane. 2) 
The binding of oligomycin simultaneously to residues of both the stationary and moving 
subunits with in the complex, effectively “glues” them together and prevents rotation. 3) The 
sheer bulk of oligomycin is likely to prevent the rotation by acting as a “stick in the spokes”. 
This last point would be mostly a contributing factor to the binding of the antibiotic to the 
proton translocating residues on both the stationary and moving subunits with in the Fo 
domain.
It was found that out of the three forms of oligomycin that were docked to the model of the 
Fo domain of ATP synthase; it was the B and C forms that bound more effectively despite the 
A form being that which is naturally more abundant. However, owing to the A form’s natural 
abundance, it is this that dominates the resulting effect. The calculated binding energies, 
converted into binding constants, correlate with those in the literature for experimental 
values. The ligating group 0(24) of the oligomycin structure appears to be the main group on 
the antibiotic, that is responsible for binding to ATP Synthase.
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Figure 118: Stereo view of the top residues involved in ligand binding, Model 1. Residues coloured 
according to function: Red: acidic, Blue: basic, Pink: neutral hydrophilic, Green: aliphatic.
R^G_210
Figure 119: Stereo view of the top residues involved in ligand binding, Model 2. Residues coloured 
according to function: Red: acidic, Blue: basic, Pink: neutral hydrophilic, Green: aliphatic.
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The modelling of the molecular orbitals of the anomalous bond found in the A form indicated 
a form of twisted n system around this bond. The length and geometry of the bond suggested 
delocalisation of electrons, resulting in a bond length that lies between that of a single and 
double bond. For the purposes of docking oligomycin A to the FO domain of ATP synthase, 
it was decided that two different forms of oligomycin A should be docked; the first where the 
anomalous bond is a single bond and the second where it is a double bond. The end result of 
docking of these differing forms of oligomycin A was that the form with the double bond 
made more regular contact with the binding site implying the lack of rotational mobility at 
this point, alters the way in which the ligand binds to the receptor.
Further work: HNF4a
Computational modelling of the phosphorylation point at Ser78 would doubtless provide 
further insight into this interaction and the effect on the ligand binding and dimerization of 
HNF4a.
In order to confirm the hypothesis of how the repressive domain of HNF4a functions, a 
model of the full homodimer structure, including the F-domain, would need to be 
constructed. It must be reiterated that the model of the truncated form of HNF4a (amino 
acids 49-369) will not be representative of the full length structure. However, modelling of 
the F-domain would go a considerable way to addressing this.
Interactions highlighted here including previously unseen interactions would be a good 
starting point for the modelling of any known or unknown mutations that are or may be 
involved in maturity onset diabetes. This would shed light on the way in which they influence 
the function of the structure, which may eventually lead to therapies that minimize the effect 
of these mutations.
Further work: Oligomycin binding to ATP Synthesis
Investigating the binding of the three forms of oligomycin further would involve a molecular 
dynamics simulation of a bound conformation of oligomycin with in the binding site. This 
would clarify how the antibiotic prevents rotation of the c-ring with respect to the stationary 
subunits under dynamic conditions, as opposed to in a stationary system.
The information resulting from these docking calculations could form the basis for the design 
of new inhibitors for the E. coli ATP Synthase.
Modelling of the anomalous bond was carried out with a relatively small basis set on a 
fragment of the oligomycin structure. It would be advantageous to perform a more detailed
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set of calculations using a maximal basis set on a full structure of oligomycin A. This would 
give a more accurate description of the molecular orbitals surrounding the anomalous bond.
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